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Investigation of Multidrug Efflux Transporter AcrB in Escherichia coli: Assembly, 
Degradation and Dynamics  
 
  The Resistant Nodulation Division (RND) super family member, tripartite AcrA-
AcrB-TolC efflux pump, is a major contributor in conferring multidrug-resistance in 
Escherichia coli. The structure of the pump complex, and drug translocation by functional 
rotation mechanism have been widely studied. Despite of all these data, the dynamics of 
the assembly process of the pump and AcrB during functional rotation in the process of 
drug efflux remains poorly understood. My thesis focuses on understanding the pump 
assembly process, dynamics of AcrB in functional rotation mechanism, and also investigate 
the mechanism of degradation of AcrB facilitated by a C-terminal ssrA tag.  
In the first project, I studied the impact of relative flexibility at the inter-subunit 
interface utilizing disulfide bond crosslinking, minimum inhibitory concentration (MIC), 
and EtBr efflux assay. Six inter-subunit disulfide links were inserted into the periplasmic 
domain of AcrB using site-directed mutagenesis. Based on results from MIC measurement, 
the double Cys mutants tested led to equal or higher susceptibility to AcrB substrates 
compared to their corresponding single mutants. EtBr accumulation assays was conducted 
utilizing Dithiothreitol (DTT) as the reducing agent. In two cases, the activities of the 
double Cys-mutants were partially restored by DTT reduction, indicating the importance 
of relative inter-subunit movement in the respective location for function. In addition, 
crosslinking at the other 4 sites did not have such an effect. 
 In the second project, I tested the effect of over-expressing functionally defective 
pump components in wild-type E. coli cells to probe the pump assembly process. The 
incorporation of defective components is expected to reduce the complex's efflux 
efficiency and lead to the so-called “dominant negative” effect. The study examined two 
groups of mutants defective in different aspects and found that none of them demonstrated 
the expected dominant-negative effect, even at concentrations many folds higher than their 
genomic counterpart. Based on the data, the assembly of the AcrAB-TolC complex appears 
to have a proof-read mechanism that effectively eliminated the formation of the futile pump 
complex.
Moreover, I utilized a novel tool- transposons library creation in studying the possible other 
proteases that contribute to the degradation of the AcrB-ssrA. Using the next-generation 
sequencing, I identified the already known clpX gene, and MIC and western blot analysis 
confirmed the results. While this result demonstrated the effectiveness of the strategy, the 
current library size is too small and does not yield novel genes related to AcrB-ssrA 
degradation. 
KEYWORDS: multidrug efflux pump, AcrB, assembly, disulfide, conformational 
changes, ssrA  
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CHAPTER 1. Introduction 
1.1 Discovery and history of Antibiotics 
Human life expectancy during the middle ages was low, and one main reason for 
this was infectious diseases. During this time, infectious diseases were one of the primary 
causes of mortality, and bacterial infections were among the common causes of these 
infectious diseases1. Tuberculosis, bubonic plague, anthrax, and cholera, for example, 
were all widespread infections2. However, with the discovery of antibiotics, this all 
changed. Mycophenolic acid isolation by Bartolomeo Gosio in 1893 was regarded as the 
first pure isolation of an antibiotic agent3. Following this initial impetus, the enormous 
efforts from scientists worldwide led to the discovery of a vast array of antimicrobial 
agents, which has been a great boon in improving human life expectancy and the quality 
of life.  
Antibiotic is derived from an antonym to symbiosis: "antibiose." Selman Waksma 
first used the term "antibiotic" in 19423, 4. In 1890, Paul Vuillemin used this word to 
describe the relationships between different microbes such as bacteria vs. protozoa, fungi, 
and bacteria. Antibiotics or antibacterials are natural secondary metabolites produced by 
bacteria and fungi, consisting of inhibitory or lethal/killing properties against bacteria.  
Natural anti-fungal, anti-viral, and antibacterial substances have been used as 
remedies for a long time5. For example, in Jordan, red soils are utilized as antibiotics, and 
several herbals are exploited in traditional Chinese medicine as antimicrobial agents. 
Qinghaosu (artemisinin), a traditional Chinese medicinal, was later revealed to be a potent 
anti-malarial drug. This was isolated from Artemisia plants in the 1970s 6 
The emergence of the organic synthesis of antibiotics in the 19th century ushered 
in the discovery of numerous antibacterial drugs. The first man-made antibacterial agent 
was arsphenamine synthesized by Alfred Bertheim, which was approved as a drug in 1910. 
Later, in 1928, Alexander Fleming observed a Staphylococcus aureus plate had been 
contaminated with the fungus Penicillium notatum, (now P. chrysogenum). He observed 
an intriguing pattern on the plate. Closer to the fungus, the bacteria were not growing, 
marked by clear areas on the plate7. The extract from P. notatum was later named penicillin 




Gram-positive ones, ever since7. In 1940, commercial production of penicillin began and 
was used to treat soldiers injured in World War II. The X-ray crystallographic structure of 
penicillin was analyzed by Dorothy et al., who categorized it as the first member of the β-
lactam family8.  
The discovery of penicillin ushered in a new era of antibiotics. With the 
development of techniques and accessibility, scientists developed various antibiotics by 
adding different functional groups. The timeline of antibiotic development is shown in 
Figure 1.1. The period between 1940 to 1960 is considered the golden era of antibiotics 
development. Over 100 novel antibiotics have been introduced to the market during this 
period due to the rapid identification and characterization of compounds with antibacterial 
activities. The subsequent significant antibiotic discovery was the sulfonamide groups. 
After that, another milestone was achieved in 1943 by the discovery of the aminoglycoside 
antibiotics streptomycin. This antibiotic group exhibited activity against both Gram-
positive and Gram-negative strains. The majority of these antibiotics were produced 
through fermentation methods except chloramphenicol which was synthesized.   
 
Figure 1.1 The timeline of antibiotic discovery and development of antibiotic resistance5. 
Copyright © 2010, American Society for Microbiology. 
 
Based on the mechanism of action, antibiotics can be divided into two major 
groups. i) bacteriostatic; these inhibit bacterial growth by interrupting the major cellular 
processes such as DNA replication, protein biosynthesis, and cellular metabolism (e.g., 





ii) bactericidal- these antibiotics kill bacteria by disturbing cell membrane 
permeability, disrupting cell wall synthesis, and essential bacterial enzymes (e.g., 
penicillin, cephalosporin). The major groups of antibiotics and their mechanism of action 
are summarized in Table 1. 
 
1.2 Antimicrobial resistance, the current development, and challenges 
Scientific knowledge and technology have immensely contributed to the fight 
against microbes and benefited human and animal health. The use of antimicrobial drugs 
has been one of the most successful therapies in human and veterinary medicine9. Even 
though antibiotics are powerful in treatments, they lose their efficiency over time. This loss 
leads to the survival of a subpopulation of bacteria that evolve to be resistant to the drugs. 
Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites 
change over time and no longer respond to the antimicrobial drugs. The overuse of 
antimicrobial agents in healthcare and veterinary, agriculture, and the poorly regulated 
antibiotic market has significantly contributed to developing resistant strains against 
antibiotics10-12  
The first antibiotic-resistant strain was found soon after the discovery of penicillin. 
A Staphylococcus strain was found to be resistant to penicillin, and as an alternative, 
methicillin was developed13. Later, with the increase of antibiotic usage, more resistant 
strains emerged.  
At present, AMR is one of the major threats to global health. The continuous 
evolvement of pathogenic microbes against the developed and available drugs is menacing 
humanity by causing deadly infections14-16. The efforts by the scientific community to 
characterize and develop new antibiotics had helped us reduce the impact of resistant 
strains temporarily. However, as new strains of resistant bacteria emerge, the battle proves 
to be a difficult one17. Currently, there are resistant bacteria to all the available antibiotics, 
causing a huge problem in treating bacterial infections. According to the Centers for 




million people are infected with antibiotic-resistant bacteria or fungi. As a result, more than 
35,000 people lose their lives each year in the United States15, 16.  
Bacteria develop resistance to antibiotics through a variety of mechanisms. 
Horizontal gene transfer during cell divisions, overexpression of specific genes, decreased 
membrane permeability and increased efflux, antibiotic inactivation, modification of the 
drug target site, and creation of by-pass reactions to prevent inhibitory effects are a few 
such mechanisms 18. Among the drug-resistant bacteria, more problematic ones are placed 
in a group called ESKAPE, named as an acronym for six bacteria; Enterococci, 
Staphylococcus aureus, Klebsiella pneumoniae Acinetobacter baumannii, Pseudomonas 
aeruginosa, Enterobacter spp. 
There are several approaches that we can consider in fighting against the pathogenic 
bacteria, i) Reduction in the spread of bacterial pathogens through the maintenance of 
personal hygiene and public health awareness ii) Development of new antibiotics as well 
as novel anti-virulence strategies to slow down bacterial evolution and resistance iii) Proper 
regulation of the antibiotics use17. Apart from reducing the spread of resistant strains, there 
is a huge requirement to develop new antibiotics. However, the period after the 1960s is 
called the lean years in antibiotic development. This is because the number of new 
antibacterial drugs developed and approved is rapidly declining. Since then, only four new 
classes of antibiotics have been approved and are available commercially19. Most recently, 
in 2015, teixobactin was developed and approved as a new antibiotic. Teixobactin acts by 
inhibiting bacterial cell wall synthesis and exhibited a high efficiency against Gram-
positive bacteria20. 
Breakthroughs in genomics and proteomics have brought new possibilities to 
antimicrobial research21-23. The first complete bacterial genome sequence became available 
in 199524, 25. However, even with such developments, the development of new antibiotics 
has lagged far behind. Antimicrobial drug discovery is a complex process mainly due to 
the inefficient penetration of compounds into bacterial cells26. Moreover, other major 
problems associated with developing new antibiotics are i) traditional and nontraditional 
methods have already identified the low hanging fruits of the antibiotics ii) it takes about 




drugs need to be safe and effective, optimization process needs to consider the suitability 
of its use in near future iv) cost of production is high19. 
From an industrial perspective, most of the early companies have stopped or 
significantly downsized their focus on antimicrobial drug research27. In the progress of 
commercial drug development, industrial research focuses on identifying broad-spectrum 
drug targets and novel inhibitors, determining the molecular mode of actions, and 
developing combination drug therapy modes28. However, there are resistance mechanisms 
against these commercial antibiotics, which raises the need to establish new inhibitors29. 
For example, studies are being conducted to produce novel inhibitors for the β-lactam 
antibiotics, which are considered the most produced and used antibiotics30. 
For acceleration of antibiotic production, in 2016, Combating Antibiotic-Resistant 
Bacteria Biopharmaceutical Accelerator (CARB-X) was launched by USA31. It is a non-
profit partnership dedicated to the rapid innovation of antibacterial agents and other 
products to combat drug-resistant bacteria. It is the world's most prominent early 
development pipeline of antibiotics. 
Even with the development of new drugs, there is always the possibility that 
bacteria will eventually develop resistance against them. Hence, regulation of antibiotic 
use is eassential6. For example, the European Union (EU) recommends the cautious use of 
antimicrobial agents in medicine32. They have regulations in monitoring the sales and usage 
of antibiotics and assessing the risk of developing drug resistance by using antibiotics on 
animals. 
1.3  Multidrug resistance in bacteria (MDR) 
Some bacteria become resistant to a broad range of antibiotics, creating multidrug-
resistant bacteria (MDR)/"superbugs." Drug resistance to all the major antibacterial classes 
in Gram-negative and Gram-positive bacteria is prevalent 33. Multidrug-resistant bacteria 
are more concerning due to their impact on available effective therapies against bacterial 
infections34. An estimated seven million deaths occur due to infections by MDR bacteria 




As mentioned above, multidrug-resistant bacteria have become one of the major 
global problems by hindering the ability to cure infectious diseases using currently 
available antibiotics35. For example, in 1991, an MDR strain of M. tuberculosis was 
isolated in the USA, which was resistant to isoniazid, rifampin, ethambutol, streptomycin, 
kanamycin, ethionamide, and rifabutin.  Due to this extreme situation, a new antibiotic, 
Bedaquiline received fast-track FDA approval to treat MDR tuberculosis. According to the 
reports by the CDC, bacterial strains have developed resistance against "last resort" 
antibiotics such as carbapenems and colistin 36. Hence, the requirement for designing drugs 
against MDR is crucial at present. Glycopeptides, quinolones, oxazolidinones, and 
antibacterial cationic peptides are being studied to see if they can be improved to be more 
effective against MDR bacteria. 37, 38. 
Drug-resistant bacteria develop resistance mechanisms due to selective pressure, 
and the acquired genetic alterations pass from generation to generation, creating a whole 
population of resistant bacteria. There are several mechanisms from which microbes 
develop drug resistance, i) genetic mutation or enzymatic alteration, e.g., production of 
MRSA by the acquisition of mecA gene ii)inactivation of drugs by enzymatic degradation, 
e.g., production of β-lactamase that hydrolyze the β-lactams antibiotics iii)antibiotic 
modification, e.g., aminoglycosides iv) Loss of porin and changes in membrane 
permeability, e.g., polymyxin resistance v)alteration of the drug target site, e.g., quinolones 
vi) overexpression of specific group proteins such as multidrug efflux pumps, e.g., 
tetracycline resistance (Figure 1.2)39, 40. Different classes of antibiotics have different 
mechanisms of drug resistance depending on their mechanism of action. These are 






Figure 1.2 The figure illustrates different mechanisms bacteria use to acquire drug 
resistance. The figure belongs to 39. 
 
The overexpression of efflux pumps is the most prevalent multidrug resistance 
mechanism, while other mechanisms lean towards single drug resistance.  Efflux pumps 
expel out a broad range of molecules, including antibiotics, dye, detergents, and salt in 
Gram-negative and Gram-positive bacteria.18, 41 Overexpression of efflux pumps reduces 
the concentration of the drug within the bacterial system by exporting it into the external 
environment, thereby contributing to intrinsic resistance42. 
 
Table 1.1 Class of antibiotics, mode of action, and resistance mechanisms.  5, 6, 9, 29 
 
Class of Antibiotics/ 
Year of first 
introduction/examples 
Mechanism of action Drug resistance mechanism 
β-lactam  (1929) 
Penicillin, Methicillin, 
Carbapenems 
Inhibition of bacterial 
cell wall synthesis.  
 
Production of the β lactamase 
Alteration of the penicillin-
binding protein (PBP)  
Sulfonamides  (1935) 
Sulfadiazine 
Inhibition of folate 
synthesis 
Enhanced efflux and alteration 






Table 1.1 (Continued) 
Polypeptides  (1939) 
Bacitracin, Colistin 
Disruption of the Gram-
negative bacterial outer 
membrane and 
membrane permeability 









Inhibition of protein 
synthesis and disruption 
of the bacterial cell 
membrane 
Phosphorylation, acetylation, 






Inhibition of protein 
synthesis 
Overexpression of efflux 
mechanism. Synthesis of 
alternative elongation factor to 
prevent ribosomal binding 
enzymatic degradation of 
tetracycline  
Lipopeptides  (1947) 
Daptomycin, Polymixin 
B 
Disruption of the 
bacterial membrane, 
inhibition of protein, 
DNA, and RNA 
synthesis 
Alteration of drug target 
Chloramphenicol (1948) Inhibition of protein 
synthesis by binding to 
the ribosome 
Enzymatic inactivation by 
acetylation, via different types 
of chloramphenicol 
acetyltransferases, target 













Modifications in target 
Enhanced efflux  
Oxazolidonones (1952) 
Linezolid, Torezolid 
Inhibition of protein 
synthesis 







in bacterial cell wall 
Target alteration by genetic 














Inhibition of protein 
synthesis  
Nucleotidylation, efflux, altered 
target 
 
1.4 Multidrug resistance mechanisms 
Among the severe bacterial infections, the majority of them are related to the MDR 
Gram-negative bacterial species43. Gram-negative bacteria have three main layers in their 
cell walls: the outer membrane, inner membrane, and peptidoglycan cell wall. Gram-
positive bacteria have two principal layers: the peptidoglycan cell wall and the inner 
membrane. These multi-layers provide an extra barrier for the drugs and other influx 
compounds. One of the multidrug resistance mechanisms in Gram-negative bacteria is 
efflux pumps. Most of these are located in the inner membrane. These pumps transport 




detailed analysis of these pumps in Gram-negative and Gram-positive bacteria has revealed 
they have versatile, functional roles in regulating compounds during infections, cell-to-cell 
communications, and the formation of biofilms44.  
Based on the sequence, structural, and functional analysis, efflux pumps are 
categorized into five major superfamilies. These are known as Resistance nodulation 
division (RND), Small molecule resistance (SMR), ATP binding cassette (ABC), 
Multidrug and toxic compound extrusion (MATE), and Major facilitator superfamily 
(MFS)45, 46 (Figure 1.3). Among these, ABC superfamily uses ATP as the energy source 
while other families use electrochemical gradient47.  ATP- dependent ABC family is 
diverse in importing or exporting solutes and functions as modulators of ion channels. An 
example of an ABC transporter is MacAB-TolC.48 
The MFS group is considered the largest and most diverse family of transporters. 
Moreover, it is known as the uniporter-symporter-antiporter superfamily; uniporters ( 
move substrates across the lipid bilayer without any coupling ions); symporters (substrate 
transport is coupled with ion and transport in the same direction) and antiporters (ion and 
substrates are moved in opposite directions). E.g., glycerol 3-
phosphate/phosphate exchanger GlpT belongs to the MFS group. Most of this superfamily 
functions as single, monomeric units. SMR family proteins are small transporters that show 
resistance against quaternary ammonium compounds and other lipophilic cations such as 
EmrE in E.coli. MATE family transporters utilize proton or sodium gradient to efflux 





Figure 1.3 Different superfamilies of efflux pumps are represented in Gram-negative 
bacterial membrane.  
Resistance nodulation division (RND), small molecule resistance (SMR), ATP binding 
cassette (ABC), Multidrug and toxic compound extrusion (MATE) and Major facilitator 




1.4.1 AcrAB-TolC efflux pump system in E. coli 
 
One of the most studied members of the resistance nodulation division (RND) 
family is the AcrAB-TolC (Acriflavin binding A and B- Tolerance Colecin) efflux system 
in Gram-negative bacteria49, 50 (Figure 1.4). AcrA-AcrB-TolC efflux pump confers 
resistance to a broad range of antimicrobial compounds such as β-lactams, tetracycline, 
novobiocin, fluoroquinolones, and fusidic acids51, 52. The study into the efflux pump 
structure has evolved over the years through the work of many research groups. Mainly, it 
is a proton antiporter and has three distinct protein groups. This tripartite assembly consists 
of an outer membrane protein TolC, a plasma membrane-spanning protein that acts as the 
transporter -AcrB, and a periplasmic membrane fusion protein AcrA that connects the two 
trans-membrane components. The role of these has been debated over the years.  The most 





recognition transporter. AcrA, which is in the periplasm, supports the formation of the 
pump by anchoring AcrB and TolC. TolC is the outer membrane channel from where the 
drug is transported out of the cell. The recent crystal structure of the efflux pump supports 
the functional rotating mechanism of drug binding and extrusion of the pump53-55.  
Upon recognition of substrate, AcrB uses the energy from the proton-motive force 
derived from substrate/proton antiport. Substrates are recruited from the periplasmic space 
and outer leaflet of the inner membrane56, 57. In the periplasm, AcrA serves as a bridge 
between the inner and outer membranes to transfer the substrate to TolC in the outer 
membrane.  58, 59. TolC, shared by many other efflux systems, exports the drug into the 
extracellular environment60, 61 The individual crystal structures of AcrA, AcrB, and TolC 
have been solved62-64. The near-atomic resolution cryo-EM structure of the entire AcrAB-
TolC complex solved by Wang et al.; reveals the intricate interacting interfaces between 
components of the pump65. The compositional stoichiometry of the complex was 
postulated to be AcrB: AcrA: TolC interaction in a 3:6:3 ratio to facilitate the transport of 
molecules across the double-membrane bacterial cell66-68. 
 
Figure 1.4 Structure of asymmetric AcrABZ-TolC pump visualized inside view.  
OM-outer membrane, IM-inner membrane. The text color represents the respective section 







1.4.2 The deep interpenetration and the Tip-to-tip Models of the AcrAB-TolC Efflux 
Assembly 
 
AcrA -AcrB-TolC is a tripartite protein complex theworking together to transport 
substrate through the periplasm and membranes out of the bacteria system.65, 69. Initially, 
by utilizing X-ray crystallography and electron microscopy and recently by novel 
techniques like cryo-EM, numerous studies have been conducted to elucidate the structure 
of these efflux pumps65, 70. The first interpreted model of the pump assembly was referred 
to as the deep interpenetration model (Figure 1.5). This model shows that AcrB and TolC 
have direct interactions with each other, with each hairpin of AcrA contacting each groove 
on TolC surface, necessary to the functional rotation mechanism71.  This was revealed from 
74 different in vivo cysteine cross-linking studies between AcrA and AcrB.   
However, another model has been recently postulated called "the tip-to-tip model." 
The AcrA hairpin in a barrel-like conformation contacts TolC in a tip-to-tip arrangement, 
as exemplified by Wang and coworkers in their published near-atomic resolution cryo-EM 





Figure 1.5 The comparison of two different proposed models for the AcrAB-TolC pump 
assembly.  
The left side shows the deep inter-penetration model, and the rights side exhibits the tip to 
tip model.72 Copyright © 2020 Marshall and Bavro, Frontiers in Molecular Biosciences. 
 
1.4.3 Exit duct of the efflux pump- Tolerance to Colicin (TolC) 
 
The outer membrane protein (OMP) of the AcrAB-TolC complex is TolC, which 
has a primary role in the expulsion of the molecules, toxins, and drugs from the cell. Many 
different biological processes share TolC in E. coli in the cell. Trimeric TolC is a 12 
stranded β-barrel composed of 493AAs in each protomer. It spans through the outer 
membrane and periplasmic space. TolC is 140 Å in length and has a funnel/tube shape with 
a tight constriction at the periplasmic end. Once a complex recruits it for assembly, it 
translocates the molecules into the external environment.73 The TolC tube is small, with a 
diameter of 3.9 Å. The two major domains, the channel domain, and the tunnel domain, 
are a 40 Å β-barrel and a 100 Å α-helical barrel, respectively.51 TolC consists of protomers 
with structural repeats, forming a six-fold symmetry. It has three docking domains that 
include a central funnel leading to the TolC lumen. It creates trimers with structural regions 







1.4.4 Adaptor protein- Acriflavine resistance protein A (AcrA) Structure 
 
AcrA can undergo large-scale conformational changes because of its flexibility. 
AcrA comprises of four domains with flexible linkers: the α-helical hairpins, lipoyl, the β-
barrel, and the proteolytically labile membrane-proximal (MP) domains.59 The other 
domains interact with AcrB except for the α hairpin that docks to TolC.61, 76-78 The 
functional relevance of AcrA has been revealed through mutational studies. These studies 
have shown that deletion of the gene locus of AcrA led to the total abrogation of the efflux 
pump activity.79, 80 AcrA or other PAPs are attached to the membrane through an acylated 
cysteine residue at position 25 or via a transmembrane residue at the N terminus. This 
attachment to the membrane is not relevant to the efflux function because even when the 
attachment is removed, the soluble AcrA retains its activity.59 
 
1.4.5 Acriflavine resistance protein B (AcrB) as a transporter 
 
AcrB is a homo-trimeric protein, of which each protomer is contains 1049 amino 
acids. AcrB is a very crucial protein for the effective functioning of the efflux pump. Hence, 
a vast majority of the studies to find efflux pump inhibitors have focused on AcrB. The 
first crystal structure of AcrB was resolved in 200263.The symmetric and asymmetric 
crystal structures of AcrB protein in the apo and substrate-bound states have been 
determined through various studies.53, 63, 81-85 Each subunit of the antiporter AcrB has 12 
transmembrane -helices that make up the transmembrane domain (TMD) and a large 
periplasmic domain (Figure 1.6).65 The TMD is necessary in proton transport and thereby 
energy production through proton motive force. Two periplasmic loops reside between 
TM1 and TM2 and TM7 and TM8, respectively. The periplasmic domain, which is further 
divided into the porter domain and the funnel/docking domain, functions in substrate 
recognition and binds to the specific drug binding pockets. Previous studies have indicated 
several drug binding sites located in the AcrB (central cavity, periplasmic site), which 
facilitates the broad range of recognition and binding capability of AcrB transporter.86 In 
the transmembrane domain, charged residues such as Asp407, Asp 408, Lys940 are 





Figure 1.6 The crystal structure of AcrB. Each protomer represents in different colors AcrB 
has two major domains, a transmembrane domain and the periplasmic head domain. The 
assembly of each monomer creates a jellyfish-like structure with a funnel-like opening57. 
Copyright © 2015 Yamaguchi et al. Frontiers in Molecular Biosciences. 
 
AcrB porter domain further divides into four major subdomains known as PN1, 
PN2, PC1, and PC2. The N terminal subdomains PN1 and PN2 are positioned between 
transmembrane helices TM1 and TM2. The C terminal subdomains PC1 and PC2 are 
located between TM7 and TM8. These subdomains have been revealed to have a 
significant role in the drug transport mechanism. Furthermore, PN1 and PC2, PN2, and 
PC1 subdomains form a rigid β- sheet structure comprising two structural subunits called 
PN1-PC2 and PN2-PC1. The funnel domain has two major subdomains, DC and DN 















Figure 1.7 This figure shows the enlarged structure of one of the AcrB monomers A) 
represent the monomer with all the subdomains and subunit structures, B) shows the 
enlarge illustrations of drug binding pockets and switch loop57. Copyright © 2015 
Yamaguchi et al. Frontiers in Molecular Biosciences 
 
It was previously reported that there are two major drug-binding sites in AcrB. The 
access pocket (AP) or proximal binding pocket (PBP) is a cleft formed by subdomains PC1 
and PC2 at the bottom of the periplasmic domain. The deep pocket (DP)/ distal binding 
pocket (DBP) located in the PN2-PC1 unit of the efflux pump is responsible for 
recognizing the low molecular mass compounds. The AP and DP sites are separated by a 
flexible, 11 amino acid residue known as a "switch loop," which is essential for drug 
transport.87, 90 These drug binding sites have unique characteristics to facilitate different 
substrate-binding, contributing to the broad range of drug specificity.  It has been reported 
that AP prefers larger substrates like erythromycin while DP favors smaller substrates like 
minocycline.87, 91-93 
The central pore is formed by associating the subdomains and is located close to 
the periplasm and recognizing high molecular mass compounds (Channel (CH)1,2,3). 
More recently, some studies suggest that certain substrates could gain access from the 





the trimer.94, 95  Therefore, the AcrB has 3 major entrance pathways for drugs; i) CH1- 
membrane surface channel entrance, ii) CH2- periplasmic entrance, and iii) CH3- central 
cavity entrance. The drugs entering these 3 pathways have different characteristics, 
allowing multidrug recognition by AcrB (Figure 1.8).  Due to multiple entry pathways, 




Figure 1.8 Side and a top-down view of AcrB showing the three main intramolecular entry 
channels in each monomer.Binding (blue) exit (pink) and extrusion (red)46. Reprinted 
from46, Copyright (2018), with permission from Elsevier. 
 
1.4.6 Functional Rotation mechanism of AcrB 
 
The drug binding and extrusion mechanisms in AcrB have been highly studied. 
They have continuously been modified with new findings, providing insight into how the 
efflux pump causes multidrug resistance in bacteria. The AcrB transporter's structural 
asymmetry shows three conformations in each protomer, reflecting a different stage of the 
drug transport cycle. This was explained by the peristaltic functional rotation mechanism 
(Figure 1.9)53-55, 96-99.These three different stages are termed open access (Loose-L), drug 
binding (Tight-T), and drug extrusion (Open-O) cycles.53, 55, 97, 100  
The AcrB has high structural homogeneity, and the protomers exhibit 






functional rotation mechanism, in the access conformation, the open and close activity of 
the external cleft between the PC1 and PC2 subdomains changes the distances between the 
protomers at the periplasmic domain. Substrates bind to AP/ PBP at the first stage. In the 
binding conformation, the cleft opens wide, whereas in the extrusion conformation, 
movement of the PC1 and PC2 subdomains causes the closure of PC2. Substrates that enter 
to AP/PBP move to DP/DBP during the transition from binding to extrusion. Thereafter, 
due to the movement of DBP, the substrate is expelled to the central funnel in TolC. The 
proton translocation across the transmembrane domain and drug binding to the porter 
domain initiate these conformational changes53. The new cryo-EM model study showed 
that ligand binding is allosterically coupled with the channel-opening. The channel remains 




Figure 1.9 Illustration of the functionally rotating ordered multidrug binding change 
mechanism mediated by AcrB82. . Reprinted from82 Copyright (2008), with permission 









1.5 Protein degradation in bacteria  
The biological networks are modulated through a series of protein expression, 
function, and degradation processes. Protein degradation in cells is an important process in 
regulating homeostasis and quality control of the cells. There are two major groups of 
proteins; ATPases associated with various cellular activities (AAA+) proteases and 
Heatshock protein70 (HSP70)102.  AAA+ proteases use the energy from ATP hydrolysis to 
unfold, modify, degrade, and transport proteins. These are essential for the regulations of 
the proteome in cells ranging from bacteria to humans103.  
The proteolytic complexes consist of proteases and peptidases. In prokaryotes, the 
proteins are degraded by the ATP-dependent pathway involving proteases including 
ClpAP, ClpXP, FtsH and, Lon104, 105. Two well-studied examples in prokaryotic protein 
degradation are AAA+ proteases ClpAP and ClpXP. The ClpXP complex consists of two 
proteins. ClpXP has a vital role in the association, unfolding, and translocation of proteins 
into ClpP for degradation. The ClpX protease consists of six AAA + subunits and a ring-
shaped motor structure. ClpP is a 14 subunits barrel-shaped peptidase  (Figure 1.10). The 
six motor subunits coordinate ATP hydrolysis, and the translocation of the protein substrate 
through the central pore is mediated by the conformational changes within a single subunit. 
These conformational changes in one subunit subsequently drive the motions of the other 
subunits106. Bacterial proteins are degraded by including a degradation peptide tag in the 





   
 
Figure 1.10 The structures of ClpX protease and ClpP peptidase.A) Top-down view of the 
ClpX protease arranges in hexameric ring. B) The side view of the ClpP arrange with 14 
subunits104. . Reprinted from104 Copyright (2012), with permission from Rightslink® 
Service and Elsevier. 
 
The protein is flagged for degradation by five major peptide motifs. These are 
categorized into two main types of peptides: C-terminal and N-terminal107. For instance, in 
E. coli the C-terminal peptide ssrA, an 11 amino acid residue (AANDENYALAA), 
facilitates the rapid degradation of soluble proteins. Furthermore, degradation signals can 
be sent via the N-rule pathway through the N-terminal tagging of the protein108. 
In general, the function of ssrA lies in the rescuing of stalled ribosomes (Figure 
1.11). The stalled ribosome is rescued by a mechanism called trans-translation. Through 
trans-translation ssrA peptide tag is added to bacterial proteins that do not have in-frame 
stop codons. Trans-translation is a crucial step in preventing negative impacts on cellular 







Figure 1.11 The pathway of ssrA tag added to the C-terminus of incompletely synthesized 
protein. Reprinted by permission from109. Copyright © 2020 Springer Applied Microbiology 
and Biotechnology 
 
Stringent starvation protein B (SspB) is a highly specific dimeric delivery/adaptor 
protein that delivers ssrA- tagged proteins to ClpXP. The SspB adaptor binds to the ssrA 
tag's first seven amino acids (AANDENY), anchoring it to the ClpXP protease, while ClpX 
detects the last three amino acids (LAA), and unfolds the protein substrate (Figure 1.12). 
110 This process enhances the degradation of ssrA-tagged proteins by ClpXP. Nyquist et al. 
used different peptide tags and demonstrated that adaptor-mediated proteolysis of the 
peptide-tagged protein substrates is comparatively efficient due to the increase in strength 
of protease-substrate contacts.111 However, it was reported that the ssrA tagged protein 
degradation in E. coli occurs even in the absence of SspB. 
 ClpX protease recognizes and binds to the peptide tag during the degradation 
process, then unfolds the attached protein substrate, followed by translocating the 
polypeptide into the proteolytic compartment ClpP, which performs the degradation of the 
unfolded polypeptide into small peptide fragments (Figure 1.12).105 Chaperone rings have 
a significant role in recognizing protein substrates by identifying specific tag sequences 
and hydrophobic motifs of some proteins (Figure 1.13).112 The peptide-tagged protein 






efficient regulation of protein degradation is difficult104. In our attempt to study the lifetime 
of AcrB in E. coli, we discovered that the introduction of a small peptide tag, the ssrA, 
leads to the complete degradation of AcrB.113 
 
Figure 1.12 Protein degradation by ClpXP protease. 
A) Model for Adaptor-Mediated Delivery of a Tagged Substrate to a AAA+ Protease 
complex B) Schematic representation of substrate recognition and degradation by AAA+ 
protease105. Reprinted with permission from © 2004 Cell Press. Published by Elsevier Inc. 
 
 
Figure 1.13 Schematic illustration of the roles of chaperone rings in ATP-dependent 
protein degradation in bacteria Protein folding chaperons, ATPases are shown in the 

















1.6  Transposons (Mobile genetic elements/"jumping genes") as a robust tool 
The advent of genomics has paved the way for improved and robust phenotyping, 
structural, and biochemical analytical methods. As one of the applications, molecular 
genetics in bacterial phenotypic studies provides greater insight into the molecular 
processes which are beneficial in medical and industrial applications. Transposons have 
become one of the most versatile tools in the molecular genetic analysis of bacteria which 
are widely applicable in the study, construction, and manipulation of different phenotypes 
in bacteria. One of the major advantages of transposons over the traditional mutagenesis 
approaches is their ability to produce mutated genes with a meager chance of multiple 
insertions.   
Transposons were first discovered by geneticist Barbara McClintock using the 
maize genome, for which she won the Nobel Prize in 1983. Transposable elements are 
generally known as "jumping genes/selfish genes".115-117 These DNA sequences move from 
one place to another in the genome. Furthermore, these are capable of moving from one 
genome to another, which is known as "Horizontal gene transfer" 117, 118. These events are 
widely found in eukaryotes and in some of the prokaryotes as well. For instance, 90% of 
the maize genome has been made up of transposons, and about 50% of the human genome 
consists of Transposable Elements (TE) 118. Transposons insertion is a random process.119  
It is important to understand the definition of terms that explain the transposons (Table 
1.2). 
Table 1.2 Definition of transposons related terms.120 
 
Term Definition 
Transposase enzyme -(i.e.Tn5),  Catalyzes the transposition reaction 
Transposon  
Transposable DNA sequence containing 
transposase recognition sequences  
Transposome 
It consists of the transposon complexed 
with the transposase. 
Transpositions 
The reaction, where the transposon is 
inserted into the target DNA 




There are two major classes of transposons; i) Class I, known as retrotransposons, 
uses RNA as a mediator to complete the transposition; ii) Class II are the DNA transposons 
flanked by terminal inverted repeats (TIR) (Figure 1.14). Furthermore, depending on the 
mode of action, they are further divided into conservative and replicative groups. In 
bacteria, there are a few types of transposons: i) IS element- insertion sequence 
transposons, transposase gene is flanked by inverted repeats (IR); conservative or 
replicative, ii) Composite transposons; conservative (Figure 1.15), iii) Transposable 
bacteriophages such as Mu phage, iv)Tn3 class transposons. 
 
Figure 1.14 A representation of Class I and Class II transposons. The image belongs to 116 
 
DNA transposons which are prevalent in bacteria, allow DNA rearrangement, 
crucial for genomic evolution. DNA transposons have a mode of action that enables 
transferring a gene from one site to another, known as the "cut and paste" mechanism. 
However, these insertions mostly happen close to the parental insertions, which is called 
"local hopping." The transposase encoded by the IS binds at or near the IR of DNA; the 
transposition reaction follows this. In composite transposons phenotype 
responsible/resistance gene, DNA region is flanked by two IS elements. These IS elements 
are responsible for the encoding of transposase (Figure 1.15). Our studies have used the 







Figure 1.15 A comparison between two major types of bacterial transposons, a)IS element 
and b) Composite transposons.122 
 
1.6.1 The applications of transposons in genomic studies 
 
The identification of transposons has led to significant discoveries in various 
scientific aspects.116, 118 The main problem associated with genome studies in terms of 
sequencing large DNA segments is sequencing an insert within the interior of a DNA. 
Alternative techniques such as genome walking/primer walking and shotgun subcloning 
have been developed to circumvent this limitation. Transposons, on the other hand, have 
proven to be an effective approach. 
One of the most prominent uses of transposons in bacteria is the generation of 
recombinant plasmids, which helps with DNA sequencing and mapping.123 Transposon 
insertions range from yeast to human DNA. These customized transposons are used as 
priming sites in the sequencing process. Advantages of using transposons include: 1) it can 
be designed to contain specific features, 2) assembly of a large number of transposons 
insertions is easy, and 3) the unique flanking sites of transposons allows rapid identification 
of insertion sites. The introduction of certain antibiotic resistance genes into bacteria (such 
as E. coli, Salmonella typhimurium, and others) in vivo is another use. Similarly, the 
insertion of replication origins into bacteria facilitates molecular cloning. Furthermore, in 





create gene "knockouts." Integrating retroviral DNA and sequencing bacterial genomic 
DNA directly from transposon insertions without cloning, as well as guiding molecular 
















Figure 1.16 A summary of different applications of transposons120. . The images belong to 
Lucigen Inc. 
 
1.6.2  The EZ-Tn5™ <KAN-2>Tnp Transposome™ system  
 
The Tn5 transposons system, which has the cut and pastes mechanism, has been 
widely used by researchers in different studies. Transposons library creations have 
facilitated the identification of genes involved in virulence as well as non-essential 
processes.125 A conjugative transposons process used in lactic acid bacteria is explained in 
detail in the review by Fitzgerlad et al. 126 
The EZ-Tn5™ <KAN-2>Tnp Transposome™ available through Lucigen Inc. 
(Middleton, WI) is based on the stable complex interaction between the EZ-Tn5 
transposase enzyme and the kanamycin-2 transposon. It provides an efficient method for 





mutant. This system includes the antibiotic resistance gene- kanamycin. Also, the ends of 
transposons are flanked by 19 bp repeats known as Mosaic Ends (ME). ME act as the EZ-
Tn5 Transposase recognition sequences (Figure 1.17).120 
The transposome system is incorporated into the cells via electroporation, and once 
inside, the Tn5 enzyme is activated by cytosolic Mg2+. 127, 128 This activation leads to the 
random insertion of transposons into the host genome, resulting in gene disruption, 
inactivation, random mutations, and ultimately functional changes. The modified EZ‐Tn5 
transposase is highly reliable and more efficient than the wild‐type Tn5 transposase.129  
The transposon insertion happens in the genomic DNA. The primers included in 
the kit can be used for bi-directional DNA sequencing to determine the insertion site. The 
Tn5 transposition process involves the binding of transposase monomers to the 19 bp 
mosaic ends and oligomerization of the end-bound transposase monomers. The blunt end 
cleavage is subsequently performed, resulting in the formation of a transposome complex 
that requires Mg2+ ions from the host cell. The next step binds to the target DNA; followed 
by strand transfer of the transposon 3′ ends into a 9 bp target sequence.124 The insertion 
process results in small gaps which are filled by host enzymes. These gaps create short 
duplications of sequences that are called target site duplications (TSD).130 This process of 







Figure 1.17 A  schematic representation of the transposition process. 
A) Shows tranposition by Tn5 Transposons binding cleavage and integration followed by 
the gap repair by host enzymes. Figure B)shows the enlarged version of the process that 



















CHAPTER 2. Probing the dynamics of  AcrB through disulfide bond 
formation 
 
“Reproduce  with permission from131. Copyright 2021 American Chemical Society” 
2.1  Introduction 
The multidrug resistance in bacteria has become one of the major threats in global 
health. Bacteria have developed a mechanism to evade the attack of most commercially 
available drugs. In gram-negative bacteria such as Escherichia coli, multidrug efflux 
systems are a major mechanism that confers intrinsic and increased drug resistance to a 
broad spectrum of antimicrobials.132 The overexpression of resistant-nodulation- division 
(RND) superfamily member AcrAB-TolC, a tripartite complex that spans through the outer 
membrane and the inner membrane, has been identified as an important mechanism leading 
to multidrug resistance.133-135 AcrAB-TolC is one of the major efflux systems contributing 
to the multidrug resistance in E. coli.  
This pump has an important role in transporting substances such as antibiotics, 
detergents, dyes, and free fatty acids out of the cell 46, 70, 94, 136. In this protein complex, 
TolC is a homotrimeric outer membrane channel that enables the exit of drugs from the 
cell to the external medium. AcrA belongs to the membrane fusion protein (MFP) family 
and exists in the periplasm. AcrB is a homotrimer inner membrane antiporter that couples 
the inward proton transport with the outward substrate transport. The assembly of the 
AcrAB-TolC tripartite complex has a stoichiometry of 3:6:3 for TolC:AcrA:AcrB, 
respectively.49, 70  
The assembled structure of the AcrAB-TolC pump complex has been revealed in 
several scanning electron microscopy studies,70, 137 and more recently through cryoEM 
studies, which provides insight into the molecular mechanism of transport by this pump.65, 
138 Moreover, symmetric and asymmetric crystal structures of AcrB in the apo and 
substrate-bound states has been determined.53, 63, 81-85 The antiporter AcrB functions as a 
trimer, with 12 transmembrane α helices and a large periplasmic domain in each subunit.65 




proton motive force to energize drug efflux. In the periplasmic domain of each subunit, 
there are multisite drug- binding pockets, which enable a broad range of drugs to enter and 
bind, and subsequently exit through efflux.74, 91 
The asymmetric structure of AcrB revealed novel insight into the drug binding and 
transport mechanism of the pump. The AcrB periplasmic domain divides into two domains, 
the porter (pore) domain and the funnel (previously known as “docking”) domain (Figure 
2.1). Porter domain is further categorized into four subdomains as PN1, PN2, PC1, and 
PC2. The funnel domain has two major subdomains, DC and DN. PN1 and PC2 
subdomains together form a rigid β- sheet structure, in a similar way PN2 and PC1 form a 
β-sheet. 
Hence, in previous reports, the porter domain has been divided into two structural 
subunits called PN1−PC2 and PN2−PC1.87, 88 The substrate access and transport pathway 
is formed between these two structural units. The analysis of crystal structures has revealed 
that a distal/deep binding pocket is located in the PN2−PC1 unit. Subdomains PC1 and 
PC2 form the cleft in the bottom of the periplasmic domain, which is another drug-binding 
pocket termed the proximal binding site. PN1 and PN2 form the drug exit pathway 
connecting to the central pore.53, 88, 139  
Substrates can access the AcrB binding pocket from the periplasm or the outer 
leaflet of the inner membrane, through entry points/vestibules near promoters.53 More 
recently, some studies suggest that certain substrates could gain access from the cytoplasm 
through the central cavity or the trans- membrane-embedded external surface of the 
trimer.46, 95 In the asymmetric AcrB structure, each protomer exhibits conformational 
differences representing each stage of the drug transport cycle, open access (loose-L), drug 
binding (tight-T), and drug extrusion (open-O)53, 55, 97. This proposed mechanism is termed 
the peristaltic functional rotation mechanism 53-55, 96-99.According to the functional rotation 
mechanism, the external cleft between the PC1 and PC2 subdomains opens and closes, thus 
changes the distances between the protomers at the periplasmic domain. In the binding 
conformation, the cleft opens wide. Also, in the extrusion conformation, the cleft closes 
through the movement of the PC1 and PC2 subdomains. These conformational changes are 





Disulfide bond trapping is an effective method in studying the conformational 
changes in proteins. Cysteine residues are introduced into the desired locations through 
site-directed mutagenesis, and then disulfide bond formation is monitored. For proteins in 
gram-negative bacteria, sites located in the periplasmic domain are normally chosen for 
mutation since disulfide bonds form readily in this cellular compartment140. In this study, 
we introduced inter-subunit disulfide bonds in the periplasmic domain of AcrB. Through 
ethidium bromide (EtBr) accumulation assays and drug susceptibility assays, we have 
investigated how the Cys mutation and disulfide bond introduced at each specific location 
affected the function of AcrB. 
 
 
Figure 2.1Locations of the six Cys pairs in the structure of AcrB  
a) Structure of an AcrB trimer showing the color-coded Cys pairs. Only mutated residues 
in the light purple subunit and their partners are shown for clarity. (b) Organization of the 
subdomains in the porter domain. The locations of disulfide bonds are shown as dots. 










2.2  Materials and Methods  
2.2.1 Bacterial Strains, Plasmids, and Growth Conditions 
 
Plasmid pQE70-CLAcrB, which encodes a cysless AcrB, was used as the template 
to create AcrB double cys mutations141 The two intrinsic cysteines in CLAcrB were both 
replaced by alanine to reduce the potential of nonspecific disulfide bond formation. The 
cysless AcrB is fully functional142, 143.Mutations were introduced using the Quikchange 
site-directed mutagenesis kit following the manufacturer’s instruction (Agilent, Santa 
Clara, CA). Primers used in the study were listed in Table 2.1. E. coli strain BW25113 and 
BW25113ΔacrB were obtained from Yale E. coli genetic resources. Bacteria were cultured 
at 37 °C with shaking at 250 rpm in Luria broth (LB) media unless otherwise noted. 
 
Table 2.1 Primers used in this study 
 
 
Construct Primer (5’-3’) 
AcrB_G51C_F CCTCCTACCCCTGTGCTGATGCGAAAAC 






AcrB_P116C_R CTTCTTGCGGCAGCAAACACATCGCCAGCTG  
AcrB_S167C_F GAAAGATGCCATCTGTCGTACGTCGGGC  
AcrB_S167C_R GCCCGACGTACGACAGATGGCATCTTTC 
AcrB_N70C_F GAACAGAATATGTGCGGTATCGATAACC 
AcrB_N70C_R GGTTATCGATACCGCACATATTCTGTTC  
AcrB_F316C_F GAAGATGGAACCGTGTTTCCCGTCGGG 
AcrB_F316C_R  CCCGACGGGAAACACGGTTCCATCTTC  







2.2.2 Drug Susceptibility Assay.   
 
The MIC   was determined for erythromycin, novobiocin, ethidium bromide (EtBr), 
and tetrapheynlphosphonium chloride (TPP) following the CLSI guidelines.144 Briefly, 
overnight cultures of the indicated strain were diluted to a final concentration of 105 
CFU/mL in fresh Muller Hinton Broth 2 (cation adjusted) media (Millipore Sigma, St. 
Louis, MO) in a 48-well microtiter plate containing the indicated compounds at two-fold 
serial dilutions. Plates were incubated at 37 °C with shaking at 200 rpm for 17 h, and the 
absorbance at 600 nm (OD600) were measured to identify the lowest concentrations with 
no observable cell growth. 
 
2.2.3 Protein Purification, Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE), and Western Blot Analysis. 
 
Five milliliters of cells were cultured overnight at 28 °C with shaking at 250 rpm. 
The next morning, cells were pelleted and resuspended in 1 mL of phosphate buffer 
containing 10 mM iodoacetamide (IAM) and phenyl- methylsulphonyl fluoride (PMSF) 
(1:1000 dilution of a saturated ethanol solution),and sonicated for 1 min followed by 
centrifugation for 10 min at 15 000 rpm. The supernatant was removed, and cell pellets 
Table 2.1 (Continued) 
AcrB_Q726C_F  GAAGATACCCCGTGCTTTAAGATTGATATCG  
AcrB_Q726C_R  CGATATCAATCTTAAAGCACGGGGTATCTTC  
AcrB_S233C_F CAGCTTAACGCCTGCATTATTGCTCAG  
AcrB_S233C_R CTGAGCAATAATGCAGGCGTTAAGCTG 
AcrB_R765C_F CGACTTTATCGACTGTGGTCGTGTGAAG 
AcrB_R765C_R CTTCACACGACCACAGTCGATAAAGTCG  
AcrB_G689C_F  GATTGACCAGGCTTGCCTTGGTCAC  
AcrB_G689C_R GTGACCAAGGCAAGCCTGGTCAATC 
AcrB Seq2_R GTGTTGCACGCATGGTAATC 




were resuspended in 0.2 mL of phosphate-buffered saline (PBS) + 2% Triton-X100 
containing 10   mM   IAM.   The   samples   were   incubated   at   room temperature with 
shaking for 45 min and centrifuged again for 10 min. The supernatant was used for SDS-
PAGE and Western blot analysis. 
For Western blot analysis, a disulfide bond was reduced either by incubating with 
10% β-mercaptoethanol (BME) for 10 min or 50 mM dithiothreitol (DTT) for 1 h as 
indicated. After transferring to the poly(vinylidene difluoride) (PVDF) membrane, protein 
bands were detected using an anti-AcrB polyclonal (Rabbit) antibody raised to recognize 
a C-terminal peptide corresponding to residues number 1036−1045145.The membrane was 
then washed and incubated with an alkaline phosphatase-conjugated Goat anti-Rabbit 
secondary antibody. The BCIP/NBT (5-bromo-4-chloro-3′-indolyphosphate and nitro-blue 
tetrazolium) solution was used to stain the membranes. 
 
2.2.4 EtBr Accumulation Assay.  
 
The EtBr assay was performed following the established procedure with slight 
modification.146 Briefly, cells were grown in 15 mL of LB media until the mid-log phase 
(OD600 of 0.6−0.8). The bacteria were then centrifuged at 3000g for 15 min and washed,  
the cell suspension was loaded into a cuvette and monitored using a fluorescence 
spectrometer (Perkin-Elmer LS 550), at excitation and emission wavelengths of 520 and 
590 nm, respectively. After ∼40 s, 1 mL of EtBr was added to a final concentration of 10 
μM and to make final OD600 of cell suspension 1.0, and the emission was monitored for an 
additional 600 s. For the samples with DTT treatment, cells were incubated with 50 mM 
freshly prepared DTT for 1 h at room temperature before loading into the cuvette. 
2.3 Results and discussion 
2.3.1 Inter-Subunit Disulfide Cross-Linking Construction.  
 
The functional rotation mechanism proposed first in 2006 highlighted the 
importance of AcrB conformational change during substrate efflux.53, 55 During this three-




conformational changes are driven by the proton translocation into the cytoplasm from the 
periplasm through a pathway along the transmembrane domains of AcrB. As discussed 
above, the relative locations of the periplasmic subdomains change during the functional 
rotation. This cycling mechanism suggested that AcrB acts as a peristaltic pump through 
the opening and closing of the drug-binding pockets and access to the TolC. Furthermore, 
it has been speculated that the conformational changes caused by substrate binding and 
proton motive force may transfer through AcrA bound to the cleft.53  Using the online 
server of “Disulfide by Design 2.0” (http://cptweb.cpt.wayne.edu/DbD2/),147 we identified 
six sites on the inter-subunit interface to introduce Cys pairs and used these pairs to study 
the flexibility and relative conformational change at the corresponding locations. 
The locations of the six cys pairs are shown in Figure 2.1. Residues G51, N70, 
Q123, and P116 are located in the PN1 subdomain. S167 and F316 are in the PN2 
subdomain. Q687 and G689 are in the PC2 domain. A215 and S233 exist in the long-
extended loop that penetrates deep into the neighboring subunit. R765 exists at the tip of a 
long loop formed by the C- terminal half of AcrB, which is equivalent to the extended loop 
in the N-terminal half of AcrB. Q726 is located at the boundary between PC2 and the DC 
domain. These introduced cysteine pairs were expected to form crosslinks at the inter-
subunit interface between the PN1−PN2 subdomains (N70C/ S167C), PN1−PN1 
subdomains (P116C/Q123C), PN2−PC2 subdomains (F316C/Q687C), the loop and DC 
subdomain (S233C/Q726C), the loop and PN1 subdomain (G51C/ A215C), and the PC2-
DC subdomains (G689C/R765C). From the four subdomains in the porter domain, 
PN1−PC2 and PN2−PC1 form the binding pockets. The proximal binding site involves 
PC1−PC2 interaction, and PN1−PN2 is important in the exit stage of the substrate.87 
Furthermore, V105C in the PN1 domain, which has been reported to form a disulfide bond 
in an AcrB trimer, was used as a control to reveal the migration position of a disulfide 
bond-linked dimer.148 Cell lysate samples prepared from BW25113ΔacrB and 
BW25113ΔacrB transformed with plasmid pQE70-CLAcrB were used as the controls. In 









Figure 2.2 Western blot analysis of disulfide bond formation in AcrB mutants.  
(a) Double-cysteine mutants, with nonreduced samples shown on the left and reduced 
samples shown on the right. (b) Single-cysteine mutant samples without reduction. Bands 
in the molecular weight marker are highlighted using black arrows. From top to bottom, 
the arrows correlate with molecular weights of 245, 190, 135, 100, 80, and 58 kDa. 
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2.3.2 Detection and Quantification of Disulfide Bond Formation. 
 
The formation of disulfide crosslinks was analyzed using Western blot analysis 





oligomers (Figure 2.2a). IAM was added before the lysis of the cells to prevent the 
formation of a disulfide bond during the cell lysis and analysis process. An unknown band 
close to the 58 kDa marker could be observed in all samples, including the negative control. 
This band has been observed in previous studies using the same antibody149. It could be an 
unknown protein that also contains a stretch of a similar peptide like the one used to raise 
the antibody. Since this nonspecific band is well separated from those of the AcrB band, it 
does not interfere with the interpretation of the data. The intensity of this nonspecific band 
also served as a loading control. Otherwise, the cell lysate prepared from BW25113ΔacrB 
did not have a protein band, confirming the good specificity of the antibody. The 
background construct CLAcrB migrated with an apparent molecular weight of ∼100 kDa, 
consistent with a monomer. The oligomers formed by other Cys pair constructs are likely 
dimer or trimers. The treatment with 10% β-mercaptoethanol led to a complete reduction 
of oligomers to monomers, further confirming that the high-molecular-weight bands were 
formed due to disulfide bonds. The expression level of most Cys pair constructs was similar 
to that of CLAcrB, while the P116C/Q123C pair seemed to express significantly less.  
Furthermore, Western blot analysis of single-cysteine mutations revealed that no 
high-molecular-weight oligomers were present, confirming that disulfide bonds were 
formed between the pair of cysteines (Figure 2.2b). The mobility of oligomers was different 
for different Cys pairs. In an AcrB trimer containing a Cys pair at each inter-subunit 
interface, there are four possible products: a circular trimer trapped with three disulfide 
bonds, a linear trimer trapped with two disulfide bonds, and a disulfide bond trapped dimer 
plus a monomer. We included V105C in this study as a mobility marker, as it would migrate 
as a monomer and a disulfide bond-linked dimer. Through comparison with the V105C 
dimer bands, it appeared that the mobility of P116C/Q123C, G51C/A215C, and 
N70C/S167C oligomers seemed to be closer to that of the V105C dimer with an apparent 
molecular weight of ∼200 kDa, and the oligomer formed in F316C/Q687C, 
G689C/R765C, and S233C/Q726C constructs migrated slower than the V105C dimer and 
with apparent molecular weight larger than the highest band in the marker (245 kDa). 





While all Cys pair mutants formed a significant portion of disulfide bond-linked 
oligomers, they all have a monomer population. We used the software ImageJ to analyze 
the percentage of crosslinked products in each of the mutants.150 The percentage of 
crosslinked oligomers ranged from 53 to 75% (Table 2.2). Several factors may affect the 
level of disulfide bond formation between two residues in the structure of a protein, the 
distance between the residues, the compatibility of the geometry of the Cys pair to that of 
a disulfide bond, and the intrinsic flexibility of the relevant protein regions including both 
the backbone and the side chain (the B-factor).147 We noted that one of the Cys pairs we 
created in this study, S233C/Q726C, have been reported in a previous study by Seeger et 
al.151. The previously reported cross-linking level of 17.0 ± 0.4% is significantly lower than 
our observation (69.1 ± 6.6). The difference could be due to differences in the cell culture 
and sample procession procedure. An extra band could be observed at ∼120 kDa, which 
disappeared upon reduction. We   speculate   that   this   could   be   a   different   protein 
conformation that was trapped by the disulfide bond. This band could also be observed, 
although at a lower concentration, in the study by Seeger et al. 151 
 
2.3.3 Functional Analysis  of  Cysteine  Mutations through Drug Susceptibility 
Assay. 
 
To evaluate the impact of the introduced Cys mutations and subsequent formation 
of disulfide bond on AcrB function, we measured the MIC of BW25113ΔacrB transformed 
with plasmids encoding each single or double Cys mutant. Four known AcrB substrates 
were used in the assay (Table 2.3). If relative movement at the respective sites is important 










Table 2.3 MIC (μg/mL) Values for E. coli Containing Single- or Double-Cysteine AcrB 
Mutants 
  
Plasmid novobiocin erythromycin EtBr TPP 
none 8 4 16 16 
CLAcrB 128 128 256 512 
S167C 64 64 128 512 
N70C 128 64 128 512 
N70C/S167C 64 64 128 512 
Q123C 64 64 128 256 
P116C 64 64 256 512 
P116C/Q123C 32 64 128 256 
G51C 64 128 128 256 
A215C 128 128 256 512 
G51/A215C 64 128 128 256 
Q726C 64 128 256 512 
S233C 128 128 256 512 
S233C/Q726C 64 128 256 512 
F316C 64 64 256 512 
Q687C 128 128 256 512 
F316C/Q687C 16 16 32 32 
R765C 64 64 256 512 
G689C 64 64 256 512 
G689C/R765C 32 32 128 256 
V105C 16 32 64 128 
V105G 32 32 128 128 
 
 
The behavior of the constructs could be clustered into two groups. In the first group, 
the Cys pair mutants behaved similarly as the less active single mutant for most of the 
substrates tested. Four out of the six constructs belonged to this group. Strains containing 




positive control CLAcrB for TPP, while the MIC of the other three compounds was reduced 
by half. The Q123C mutation reduced the MIC of all four drugs tested by half, while the 
P116C mutation only affected the MIC of novobiocin and erythromycin. The double 
mutant P116C/Q123C behaved similar to the single Q123C mutant except for novobiocin, 
for which the MIC was further reduced by 2-fold. The G51C single mutation led to a 2-
fold reduction of the MIC of G51C/A215C double mutation had similar MIC as the G51C 
single mutant for all four test compounds. Strains containing Q726C, S233C, or the 
corresponding double mutant had similar MIC as the positive control for all substrates 
except for novobiocin. The Q726C single mutant and the double mutant displayed a 2- fold 
reduction in MIC for novobiocin. 
The other two pairs belong to the second group. For the F316C/Q687C pair and the 
G689C/R765C pair, strains containing the double mutants displayed lower MICs for all 
four compounds tested than the corresponding single mutants. While the Q687C mutation 
did not lead to an observable reduction of activity, the F316C mutation led to a 2-fold 
reduction of MICs for novobiocin and erythromycin. The F316C/Q687C double mutant 
displayed an 8- to 16-fold reduction in MIC for all substrates. Similarly, R765C and G689C 
single mutants had similar activity as the positive control for EtBr and TPP, and a 2-fold 
reduction of MIC for erythromycin and novobiocin. The double mutant showed lower 
activity toward all four compounds with a reduction in MIC of 2- to 4-fold. For this group, 
there is a possibility that the observed higher susceptibility of the cysteine double mutants 
is due to the restriction of conformational change resulted from crosslinks, which impaired 
the efflux activity of AcrB. We have also included V105C and V105G mutants in this study. 
As expected, mutation of V105 led to a significant reduction of efflux activity as the MICs 
of all four compounds tested were reduced. For novobiocin and EtBr, the MICs of the strain 
containing V105C were 2-fold lower than that of the V105G. 
 
2.3.4 Restoration of the Activity by Dithiothreitol (DTT) Detected Using EtBr 
Accumulation Assay.  
 
If the previously observed higher drug sensitivity is a result of disulfide bond 




investigated using the EtBr accumulation assay. We found that DTT at 10 mM could not 
fully reduce the disulfide bonds formed in our AcrB constructs, even with 4 h incubation 
(Figure 2.3). While the portion of monomers did increase after the treatment, clear 
oligomer bands could still be observed in all cases. And for some samples, multiple 
oligomer bands could be observed after this treatment, which are likely partially reduced 
oligomers. When incubated with 50 mM DTT, disulfide bonds could be completely 
reduced after 1 h incubation (Figure 2.3). Thus, this higher DTT concentration was used 
for the accumulation assay.  
 
 
Figure 2.3 Anti-AcrB Western blot analysis of double-cysteine AcrB mutants under 
different reduction conditions.  
Left: Reduced with 10 mM DTT and incubated for 4 h at room temperature. Oligomers are 
only partially reduced. Right: Reduced with 50 mM DTT and incubated for 1 h at room 
temperature. Oligomers are fully reduced. The bands in the molecular weight marker are 
highlighted by black arrows. From top to bottom, the molecular weights are 245, 190, 135, 
and 100 kDa. 
 
Cells containing the indicated plasmids were prepared as described in Section 2.2.4 for the 
EtBr accumulation assay. We included all six pairs, as well as V105C, in the study for 
comparison. For four out of the six Cys pair constructs, the DTT treatment did not lead to 
a significant difference in the rate of EtBr accumulation (Figure 2.4). However, for the 
other two pairs, F316C/Q687C and G689C/R765C, reduced samples exhibited notably 
lower accumulation of EtBr, indicating that the formation of a disulfide bond contributed 
significantly to the reduced activity. This indicated that the reduction of disulfide crosslinks 
by DTT at these two locations had partially restored the efflux activity (Figure 2.4d,e). In 



















Figure 2.4 EtBr accumulation assay of all double-cysteine mutants with or without 
reduction. 
(a) Negative control BW25113ΔacrB (blue no DTT, red with DTT) and positive control 
BW25113ΔacrB expressing plasmid-coded CLAcrB (orange no DTT, brown with DTT). 
(b) BW25113ΔacrB expressing AcrB mutants N70C/S167C (blue no DTT, red with DTT) 
or P116C/Q123C (orange no DTT, brown with DTT). (c) BW25113ΔacrB expressing 
AcrB mutants G51C/A215C (blue no DTT, red with DTT) or S233C/Q726C (orange no 
DTT, brown with DTT). (d) BW25113ΔacrB expressing AcrB mutant F316C/Q687C (blue 
no DTT, red with DTT). (e) BW25113ΔacrB expressing AcrB mutant 
G689C/R765C (blue no DTT, red with DTT). 
 
2.5 V105 Mutations and Efflux.  
 
V105C is located in a helix close to the threefold axis of the AcrB trimer and forms 
a disulfide bond.148 It was speculated that the formation of a disulfide bond restricted the 





values (Table 2.3) for novobiocin and erythromycin, consistent with previous studies, 
indicating that the mutation significantly impacted AcrB activity.148 However, the DTT 
treatment reduced the dimer but only led to a modest reduction of EtBr accumulation in 
BW25113ΔacrB expressing V105C (Figure 2.5). To further investigate the potential role 
of the disulfide bond in activity, V105 was mutated to Gly. Accumulation of EtBr in 
BW25113ΔacrB containing V105G was higher than that in the positive control, indicating 
that the replacement of Val itself is detrimental to function. This result is consistent with 
the MIC measurement. Accumulation of the strain containing V105C was higher than that 
in the strain containing V105G, suggesting that the formation of the disulfide bond further 
impaired efflux. Upon reduction, accumulation in the V105C strain was reduced to be more 
similar to the accumulation in the V105G strain. 
 
 
Figure 2.5 Analysis of V105C and V105G. 
(a) Anti-AcrB Western blot analysis of V105C and V105G, showing the formation of a 
disulfide bond in V105C but not V105G. The molecular weight of bands in the marker is 
highlighted by black arrows. From top to bottom: 245, 190 
2.4 Conclusions 
The structure of the entire AcrABZ-TolC complex has been revealed using 
cryoEM.65, 152 More recent studies illustrated the in situ structure of the complex in E. coli 
cells overexpressing the pump components.138 While these structure insights have led to 
the answer of many questions related to the mechanism of efflux by the RND pumps, 





the AcrAB-TolC system undergoes a conformational change to carry out efflux. While the 
combination of structures, which are snapshots of proteins, and computational simulation 
cast lights on how proteins move, experimental testing of the simulation movies is critical. 
Based on the crystal structure of AcrB, we designed and engineered six Cys pairs to 
examine the consequence of these structure staples on its efflux activity. We found that for 
four pairs, the formation of a disulfide bond did not seem to have much impact on efflux, 
as the double mutant behaved similarly as the less active single mutants. Relative inter-
subunit movement at these sites does not seem to be required for efflux. 
For the other two pairs, the double mutants are less active than the individual single 
mutants, which could be potentially due to the restriction effect from the disulfide bond 
that either restricted relative movement of neighboring subunits or locked the subunits in a 
conformation incompatible with substrate binding and/or translocation. While the activity 
of the efflux pump is most conveniently evaluated using the MIC assay, the effect of 
disulfide bond on activity could not be measured this way since the high concentration of 
reducing reagent that is necessary to effectively reduce the disulfide bonds would inhibit 
E. coli growth. Alternatively, EtBr efflux could be monitored using cells containing 
reduced or nonreduced AcrB Cys pair constructs. We found that for two pairs, F316C/ 
Q687C and G689C/R765C, reduction of the disulfide bond significantly improved efflux, 
confirming the functional relevance of conformational flexibility at these sites. There 
appears to be a discrepancy between the apparent percentage of cross-linking with the level 
of reduced activities in these double mutants, which is most likely explained by the 
different growth phases the cells were harvested for the two types of experiments. For the 
activity (MIC) measurement, the proliferation of cells was monitored in the presence of 
test compounds. For the EtBr accumulation assay, mid-log phase cells were taken and used 
in the study, whereas for the cross- linking analysis, overnight cultures were taken, and 
those cells were in the stationary phase and took longer time for disulfide formation. 
Apart from the interference by disulfide bond formation on the function of AcrB, 
the reduction of the activity of the Cys pairs could be due to an unfavorable conformation 
of the disulfide dimers that interfere with the substrate binding and transport activity. 
Interestingly, the two sites with high impact on activity are located close to each other, with 




brown and yellow dots). While F316C/ Q687C forms a disulfide bond at the interface 
between the PN2 and PC2 subdomain of the neighboring subunit (brown), G689C/R765C 
linked the PC2 subdomain to the tip of the long loop formed by the C-terminal half of the 
neighboring subunit. 
Since each subunit in an AcrB trimer contains a separate and complete set of 
substrate binding residues and translocation pathway, a conformational change that is 
involved in substrate binding and extrusion should be localized more to the inside of a 
subunit. Yet, relative inter-subunit conformational change has been reported in several 
cases to be critical for AcrB function, likely due to the functional rotation mechanism in 
which the trimer needs to undergo conformational change simultaneously. Thus, some of 
the sites that are located at the inter- subunit interface are expected to be the “sensor” sites 
that need to play the role of coordinating the movement. While in other sites, including 
several sites described in this, and V225C/ A777C, R558C/E839C, V32C/A299C, and 
I235C/K728C reported in previous studies (Table 2.4), Cys substitution and disulfide bond 
formation do not have a clear impact on functions.151 These could be sites that maintain 
close contact throughout the functional rotation mechanism to maintain AcrB as a tightly 
associated, integrated, functional trimer. 
 
Table 2.4 Engineered Disulfide Bonds in AcrBa  
 
Res1 Res2 oligomer (%) activity level citation 
Inter-Subunit     
G51 A215 60.6 ± 6.80 +++ this study 
Q123 P116 53.2 ± 11.4 ++  
S167 N70 58.3 ± 5.4 +++  
F316 Q687 68.9 ± 6.4 −  
Q726 S233 69.1 ± 6.6 +++  
R765 G689 74.9 ± 6.8 −  
V105C V105C 57.9 ± 13.2 +  
Q229 R586 46.4 ± 0.5 ++ 151 





Table 2.4 (Continued) 
S562 T837 15.4 ± 1.3e +  
S132 A294 41.6 ± 0.6 +  
V32 A298 41.3 ± 1.2 +  
V32 A299 18.1 ± 1.0 +++  
Q726 S233 17.0 ± 0.4 +++  
I235 K728 23.8 ± 0.6 +++  
V225 A777 80.2 ± 1.3 +++  
Q229 T583 69.4 ± 0.5 +  
D566 T678 N/A + 97, 140 
F666 T678 N/A −  
F666 Q830 N/A +  
F316 Q687 N/A ++ 97 
F316 A688 N/A +  
F316 G854 N/A −  
Intra-Subunit     
V32 I390 82.5 ± 6.8 +++ 141 
T44 T91 100.7 ± 3.0 +++  
M184 V771 76.2 ± 4.9 +++  
T199 T749 82.7 ± 2.9 +++  





102.9 ± 6.8 




G570 A627  +++  
F572 A627  +++  
V576 A627  +++  
L578 A627  +++  
  
a+++: MIC equals to 50−100% of the wild-type MIC. ++: MIC equals to 25% of the 
wild-type MIC. +: MIC equals to 12.5% or less of the wild-type MIC. −: MIC close to 





CHAPTER 3. Insight into the AcrAB-TolC complex assembly process 
learned from competition studies 
 
Reproduced in parts with permission from153, antibiotics; published by MDPI 2021. 
3.1 Introduction 
Antimicrobial resistance, especially multidrug resistance in bacterial pathogens, is 
among the top 10 global threats to humanity 15. Among the large array of different defense 
mechanisms adapted by bacteria, the overexpression of efflux pumps has a significant role 
in conferring multidrug resistance. AcrAB-TolC is one of the most extensively studied 
efflux pump systems in Gram-negative bacteria, playing a crucial role in the multidrug 
resistance in bacteria such as Eshcherichia coli 57 , 69, 154. AcrAB-TolC is a member of the 
resistance nodulation division (RND) superfamily. AcrAB -TolC efflux pump confers 
resistance to a broad spectrum of antimicrobial compounds including β-lactams, 
tetracycline, novobiocin, and fluroquinolones 51, 52. This tripartite efflux transporter 
consists of three major protein components 135, 136, an outer membrane channel TolC, a 
periplasmic adaptor protein (PAP) AcrA, and an inner membrane proton-driven antiporter 
AcrB 70, 74, 87, 137. TolC forms a channel that spans the outer membrane and acts as the exit 
pathway of substrates translocated from the inner membrane and the periplasmic space. 
AcrA has function in stabilizing the connection between the two membrane components 
TolC and AcrB 58, 59. The RND transporter protein AcrB is responsible for substrate 
recognition and energy transduction. Upon binding of a substrate, AcrB uses the energy 
from the proton flow down its concentration gradient through a proton translocation 
pathway in the transmembrane domain to drive the conformational change necessary to 
move the substrate upward toward the exit tunnel 56, 57. TolC is shared by several efflux 
systems, hence E. coli strains deficient in TolC are more sensitive to a wider variety of 
chemicals (e. g. detergents, drugs, bile salts, and organic solvents) 60, 61. 
With the dedication of many research groups, the structure and mechanism of drug 
efflux by the RND pumps have been brought to light. The first crystal structure of the pump 




an overall length of 140 Å with 40 Å in the β-barrel domain mainly composed of β strands, 
and 100 Å in the periplasmic domain mainly composed of α-helices. The periplasmic end 
of the TolC tunnel is sealed at the resting state, which likely opens by an allosteric protein–
protein interaction mechanism 138. In 2002, Murakami et al. first reported the crystal 
structure of AcrB, followed by the proposal of the functional rotation mechanism 53, 63, 96. 
Later in 2006, Mikolosko and coworkers determined the crystal structure of AcrA. In 
contrast to the trimeric TolC and AcrB, AcrA forms a hexamer in the pump assembly 62. 
The assembled pump structure was first proposed as the “deep interpenetration model”, 
which shows that AcrB and TolC have direct interactions with AcrA wrapped around on 
the outside to strengthen the interaction 71. More recently, Wang et al. proposed a new 
model based on Cryo-EM studies, known as the “tip-to-tip model”. In this model, AcrA 
hairpins form a barrel-like conformation, contacting TolC in a tip-to-tip arrangement 65, 72. 
The recent determination of the complex structure first by cryo-EM, then by X-ray 
crystallography, confirmed the tip-to-tip model 55, 63, 82, 83, 91, 136, 138. Energy does not seem 
to be required to assemble the AcrAB-TolC complex and AcrAB could interact with the 
TolC channel to form a AcrAB-TolC complex even in the absence of known substrate 77. 
The dynamic process that leads to the formation of the complex is still elusive. 
The dominant negative effect describes the phenomena in which an excess of a 
functionless mutant of a protein in the presence of its wild type counterpart, reduces the 
observed activity due to competition from the mutant for interaction with functional 
partners of the protein of interest. In the AcrAB-TolC complex, over-expression of 
functionless AcrB or AcrA mutant in wild type E. coli strains is expected to drastically 
reduce the assembly of functional efflux complex, and thus reduce the efflux activity and 
increase the sensitivity to substrate compounds. However, we tested the overexpression of 
several functionally defective mutants in the wild type E. coli strain, but did not observe 
the expected level of reduction. We speculate that the assembly of the AcrAB-TolC is a 






3.2  Materials and Methods 
3.2.1 Bacterial strains, plasmids and growth conditions 
 
Escherichia coli BW25113 and BW25113∆acrB were obtained from Yale E. coli 
genetic resources. BW25113∆acrAB was constructed using E. coli gene deletion kit (Cat 
#K006, Gene Bridge) following the manufacturer’s protocol. Plasmids pBAD33-AcrB was 
created in our previous study155. To create the plasmid pBAD33-AcrAB,  acrAB gene was 
amplified from genomic DNA of BW25113 and cloned into pBAD33 by following the fast 
cloning method described previously by Li et al.156. Plasmids pBAD33-AcrB, and 
pBAD33-AcrAB were used as the templates to create respective mutations discussed 
below. Mutations were introduced using the Quikchange Site Directed Mutagenesis Kit 
following manufacturer’s instruction (Agilent, Santa Clara, CA). Primers used in this study 
mentioned in Table 3.1. Bacteria were cultured at 37oC with shaking at 250 rpm in Luria 
broth (LB) media unless otherwise noted. 
 
Table 3.1 Primers used in this study  
 
Construct Primer (5’-3’) 
AcrB D408A-F CATCGGCCTGTTGGTGGATGCCGCCATCGTTGTGGTAG 
AcrB D408A-R CTACCACAACGATGGCGGCATCCACCAACAGGCCGATG 
AcrB K940A-F CCATTGGGTTGTCGGCGGCTAACGCGATCCTTATCG 
AcrB K940A-R CGATAAGGATCGCGTTAGCCGCCGACAACCCAATGG 
AcrB R971A-F CTTGATGCGGTGCGGATGGCATTACGTCCGATCCTGATG 
AcrB R971A-R CATCAGGATCGGACGTAATGCCATCCGCACCGCATCAAG 
AcrB T978A-F CGTCCGATCCTGATGGCCTCGCTGGCGTTTATCCTC 
AcrB T978A-R GAGGATAAACGCCAGCGAGGCCATCAGGATCGGACG 
AcrB F178A- F GGGTGATGTTCAGTTGGCCGGTTCACAGTACGCGATG 
AcrB F178A- R CATCGCGTACTGTGAACCGGCCAACTGAACATCACCC 
AcrB I278A-F GGTGAGAACTACGACATCGCCGCAGAGTTTAACGGCCAAC 
AcrB I278A-R GTTGGCCGTTAAACTCTGCGGCGATGTCGTAGTTCTCACC 





Table 3.1 (Continued) 
AcrB F610A -R GCCGAAGCCGTTAACGGCGGCCACCGACTCAACGTTG 
AcrA P57C-F CAG ATC ACA ACC GAG CTT TGT GGT CGC ACC AGT GCC 
TAC 
AcrA P57C-R GTA GGC ACT GGT GCG ACC ACA AAG CTC GGT TGT GAT 
CTG 
AcrA T217C-F CCG ATC GTT GAT GTG TGT CAG TCC AGC AAC GAC TTC 
AcrA T217C-R GAA GTC GTT GCT GGA CTG ACA CAC ATC AAC GTA GAT 
CGG 
AcrB N191C-F CGT ATC TGG ATG AAC CCG TGT GAG CTG AAC AAA TTC 
CAG 
AcrB N191C-R CTGGAATTTGTTCAGCTCACA CGG GTT CAT CCA GAT 
ACG 
AcrB S258C-F CTG AAA GTG CAG GAT TGT CGC GTG CTG CTG CGT TCC 




3.2.2 Drug susceptibility assay 
 
The minimum inhibitory concentration (MIC) was determined for erythromycin, 
novobiocin, ethidium bromide (EtBr), rhodamine 6G (R6G) and tetraphenylphosphonium 
chloride (TPP) following the CLSI guidelines.144 Briefly, overnight cultures of the 
indicated strain were diluted to a final concentration of 105 CFU/mL in fresh Muller Hinton 
Broth 2 (cation adjusted) media (Millipore Sigma, St.Louis, MO) in a 48 well microtiter 
plate containing the indicated compounds at two-fold serial dilutions. Plates were 
incubated at 37oC with shaking at 160 rpm for 17 hrs the absorbance at 600 nm (OD600) 





3.2.3 Protein expression, SDS-PAGE and Western blot analysis 
 
For expression test, 5 mL of cells were cultured overnight at 37oC with shaking at 
250 rpm. In the next morning, the cell was inoculated with a 100-fold dilution into a 5 ml 
fresh LB media supplemented with antibiotics and grow until ~ OD600 1.0. Cells were 
pelleted and resuspended in 1 mL phosphate buffer containing phenylmethylsulphonyl 
fluoride (PMSF) (1:1000 dilution of a saturated ethanol solution) and sonicated for 1 min 
followed by centrifugation for 10 mins at 15,000 rpm. The supernatant was removed, and 
cell pellets were resuspended in 0.1 mL PBS containing 2% Triton-X100. The samples 
were incubated at room temperature with shaking for 45 mins and centrifuged again for 10 
mins. The supernatant was used for SDS-PAGE and Western blot analysis. For studies of 
disulfide bond formation, iodoacetamide (IAM) was added to a final concentration of 20 
mM in all buffers. To reduce disulfide bond, β-mercaptoethanol (BME) was added to a 
final concentration of 2% followed by incubation at room temperature for 30 mins.  
For Western blot analysis, after transferring to the PVDF membrane, protein bands 
were detected using an Anti-AcrB polyclonal (Rabbit) antibody raised to recognize a C-
terminal peptide corresponding to residues number 1036-1045145. The membrane was then 
washed and incubated with an alkaline phosphatase conjugated Goat anti-Rabbit secondary 
antibody. The BCIP/NBT (5-bromo-4-chloro-3'-indolyphosphate and nitro-blue 
tetrazolium) solution was used to stain the membranes. 
For AcrAB dissociation experiment, BW25113 or BW25113ΔacrA containing 
plasmid pBAD18-AcrA was cultured to the log phage (OD600 0.8) and arabinose was 
added to a final concentration of 0.2% (w/v) to induce the expression of AcrA for 50 min. 
The cells were then pelleted, washed, and resuspended with fresh LB. An aliquot of cell 
culture was collected, pelleted, and stored at −20 °C. The rest of the cell culture was 
returned to the shaker and cultured for 5 h, and another aliquot of sample was collected, 
pelleted, and stored at −20 °C. The last sample was collected at 17 h. OD600 of the samples 
were measured and used to adjust the sample volume collected to ensure that the same 
number of cells were used for each time point. All pellets were resuspended and sonicated 
to lyse the cells. After centrifugation, the pellet was extracted using PBS + 2% Triton for 
2 h. The mixtures were centrifuged again and the supernatants were incubated with Ni 




imidazole, and finally eluted with the same buffer supplemented with 500 mM imidazole. 
For DSP crosslinking experiments, the cell pellet was washed and then resuspended in PBS 
buffer. DSP was added to a final concentration of 1 mM, and the mixture was incubated at 
room temperature for 30 min. To stop the reaction, a Tris-Cl buffer (pH 8.0) was added to 
a final concentration of 20 mM. Cells were then pelleted, and proteins were purified 
similarly as described above. To break the disulfide bond in DSP, DTT was added to the 
sample to a final concentration of 10 mM. For Western blot analysis, Anti-AcrB polyclonal 
(Rabbit) antibody or Anti-AcrA antibody used respectively. All experiments were repeated 
at least three times. 
3.3  Results and discussion 
3.3.1 AcrB mutants defective in proton transport 
 
Several key residues have been identified in the AcrB transmembrane domain, forming the 
proton translocation pathway 55, 63, 88, 139, 157-161. We have created single alanine replacement 
mutations at each of these sites to obtain mutants AcrB-D407A, AcrB-D408A, AcrB-
K940A, AcrB-T978A, and AcrB-R971A 158, 160. The plasmid encoding of these mutants 
was first transformed into the BW25113∆acrB strain to examine their efflux activity (Table 
1). As expected, the minimum inhibitory concentrations (MICs) of most examined 
substrates against the strains containing the mutants were the same as those against the 
strains without plasmids. The only mutant that displayed significant activity is T978A, 
which remained partially active. As a positive control, we showed that transformation with 
a plasmid encoding the wild type AcrB completely restored the efflux activity with MIC 
values similar to a wild type BW25113 strain. Next, we transformed these plasmids into 
the wild-type BW25113 strain and measured the MIC. We expected the AcrB mutants to 
compete with the genomic AcrB in binding and interaction with genomic AcrA and/or 
TolC, thus reduce the number of functional efflux complexes and subsequently the drug 
susceptibility. However, we observed a two-fold reduction of MIC value in some cases, 
and no reduction others, which is consistent with an earlier study reporting the modest 
reduction of substrate susceptibility when AcrB-D407A was over-expressed in a wild -type 




Table 3.2 MIC values (µg/mL) of BW25113 or BW25113∆acrB strains containing the 
















1 NOV, novobiocin. ERY erythromycin, TPP tetraphenylphosphonium, EtBr ethidium 
bromide. R6G, rhodamine 6G, NA, nalidixic acid. ND, not determined. 
We conducted the MIC assay under the basal expression condition without 
induction to avoid the potential artifact that may arise from over-expression. To examine 
how much of each mutant actually expressed under the basal condition, we prepared 
samples from BW25113 containing different plasmids, and compared the expression level 
from the plasmid to the level of genomic AcrB. Even without induction, under our 
experimental condition, the plasmid-encoded mutants were expressed at a much higher 
level (5–20 folds higher) compared to the level of the genomic AcrB (Figure 3.1a). This 
result indicates that the lack of impact on drug susceptibility is not due to the lack of 
Substrate 1 NOV ERY TPP EtBr R6G NA 
BW25113∆acrB 
containing  
      
/ 4 4 4 8 8 1 
WT 128 64 256 128 256 4 
D407A 4 4 4 8 8 ND 
D408A 4 4 4 8 8 ND 
K940A 8 4 4 8 8 ND 
R971A 8 4 4 8 16 ND 
T978A 8 8 16 32 128 ND 
BW25113 containing       
/ 256 64 1024 512 1024 4 
WT 512 128 1024 512 1024 4 
D407A 128 64 1024 256 512 4 
D408A 128 64 1024 512 1024 4 
K940A 256 64 1024 512 1024 4 
R971A 128 32 1024 512 1024 4 
T978A 256 64 1024 512 1024 2 
expression. Even presented at a large excess, the mutants were not effective in disrupting 
the normal efflux activity. 
Single mutations on the proton relay pathway do not significantly affect the overall 
structure of AcrB. The crystal structure of a couple of these mutants have been determined 
using X-ray crystallography 158, 162. All mutants form trimeric structures similar to those in 
the wild-type AcrB 158. To examine if a mutant defective in proton translocation could still 
bind AcrA, we used two inter-subunit disulfide bonds as our yardsticks to probe the 
interaction between AcrA and AcrB. We first constructed a plasmid expressing both AcrA 
and AcrB (pBAD33-AcrAB), then introduced a pair of cysteines, one in AcrA and the other 
in AcrB: AcrA-P57C/AcrB-N191C, and AcrA-T217C/AcrB-S258C. These residues are 
predicted to be close to each other according to the “Disulfide by Design 2.0” (http://
cptweb.cpt.wayne.edu/DbD2/ (accessed on 06/01/2019))147. The formation of disulfide 
bond linked AcrA-AcrB complex was confirmed using anti-AcrA and anti-AcrB Western 
blot (Figure 3.1b). A high molecular weight complex could be detected in both blots, 
which disappeared upon incubation with β-mercaptoethanol (BME). The disulfide bond-
linked species migrated slightly differently in the gel, likely due to differences in the 
conformations of the two complexes under the gel running condition. Mutation and 
disulfide bond formation did not significantly impair efflux activity, as revealed in the MIC 
measurement (Table 3.2). Next, we introduced the D408A mutation into both constructs to 
examine the effect of this additional mutation on the formation of disulfide bond linked 
AcrA-AcrB complex. If the D408A mutation had a significant impact on the interaction 
between AcrB and AcrA, we expect to see a reduction of the intensity of the high molecular 
weight AcrA-AcrB complex. As shown in Figure 3.1c, disulfide bond formation was to a 
similar level in both constructs, suggesting that the additional D408A mutation did not 
have a significant impact on AcrA-AcrB interaction. 
To examine if the additional expression of AcrA from the same plasmid as the 
AcrB-D408A have any impact on the competition with the genomic AcrB, we introduced 
plasmid pBAD33-AcrAB-D408A into the wild type BW25113 strain and examined the 
MIC. Both AcrA and AcrB-D408A expressed at levels much higher than their genomic 






Figure 3.1 Characterization of mutants defective in the proton translocation pathway. 
 a) The point mutation did not affect expression level. Anti-AcrB Western blot analysis of 
the expression of all five mutants and the wild-type AcrB from plasmid transformed into 
BW25113. Sample prepared from plasmid-free BW25113 (\) was also prepared and loaded 
to serve as a control to highlight the difference in expression levels. (b) Anti-AcrB and 
Anti-AcrA Western blot analyses revealing the formation of disulfide bonded AcrA-AcrB 
complexes, which was reduced after incubation with BME. AcrA-P57C/AcrB-N191C 
(lane 1 and 3), AcrA-T217C/AcrB-S258C (lane 2 and 4). (c) Similar to b, with the 
additional D408A mutation introduced into the constructs. AcrA-P57C/AcrB-
N191C/AcrB-D408A (lane 1 and 3), AcrA-T217C/AcrB-S258C/AcrB-D408A (lane 2 and 
4). Molecular weight markers are labeled as “M” and the molecular weight of bands (kD) 
were indicated on the right. The expected bands for AcrA, AcrB, and disulfide bond linked 
AcrA-AcrB are marked on the left of the gels as A, B, and AB, respectively. (d) Anti-AcrB 
(left) and anti-AcrA (right) Western blot analysis of BW25113 expressing plasmid 
pBAD33-AcrAB (WT) or pBAD33-AcrAB-D408A (D408A). Samples prepared from 
BW25113 not containing plasmid was used as the control (/). For anti-AcrA Western blot, 




Table 3.3 MIC values (µg/mL) of BW25113 and BW25113∆acrAB strains containing the 
indicated plasmid encoding gene for both AcrA and AcrB. 
 
Substrate NOV ERY TPP EtBr R6G 
BW25113∆acrAB containing      
/ 4 4 8 4 16 
WT 32 32 128 128 32 
AcrA/AcrB-D408A 4 2 8 8 8 
AcrAP57C/AcrBN191C 32 16 64 64 32 
AcrA-T217C/AcrB-S258C 64 16 128 128 32 
BW25113 containing      
/ 256 32 1024 512 512 
AcrAB-WT 256 64 1024 512 1024 
AcrAB-D408A 256 32 1024 512 512 
 
3.3.2 AcrB Mutants Defective in Substrate Binding 
 
One feature of the AcrAB-TolC complex that has drawn much research interest is 
their ability to efflux a large array of substrates ranging broadly in molecular weight, 
charge, and hydrophobicity. Many mutations have been introduced in the substrate binding 
pocket in AcrB to probe their impact on the efflux of different substrates 55, 100. We chose 
three such mutants to include in this study, F610A, I278A, and F178A, since they were 
reported to have the most significant impact on efflux. First, plasmids containing single 
residue mutations at these sites were introduced into BW25113∆acrB to examine their 
activities (Table 3.3). While the F610A mutant is largely inactive, both F178A and I278A 
remained partially active, which is consistent with previous reports 163. It is clear that in 
general, single point mutations introduced at the substrate binding site are not as 
detrimental as mutations introduced in the proton translocation pathway. This is reasonable 
when considering several residues collectively form a substrate binding site, while the 




Next, plasmids encoding these mutations were transformed into BW25113 to determine 
their impact on efflux activity. Similar to proton relay pathway mutants, the MIC values of 
the strain were not significantly affected (Table 3.4). The presence of AcrB mutants 
defective in substrate binding does not display the dominant negative phenotype either. 
Table 3.4 MIC values (µg/mL) of BW25113 and BW25113∆acrB strains containing the 
indicated plasmid encoding AcrB mutants defective in substrate binding. 
 
Substrate NOV ERY TPP EtBr R6G NA 
BW25113∆acrB 
containing 
      
/ 4 4 4 8 8 1 
WT 128 64 256 128 256 4 
F610A 8 8 64 32 128 ND 
F178A 64 8 128 128 256 ND 
I278A 32 32 128 128 128 ND 
BW25113 containing       
/ 256 64 1024 512 1024 4 
WT 512 128 1024 512 1024 4 
F610A 512 64 1024 512 1024 2 
F178A 512 64 1024 512 1024 4 
I278A 512 64 1024 512 1024 4 
 
Next, we examined the expression of these mutants under the basal condition 
(Figure 3.2a). Similar as described above, the plasmid-encoded mutants were expressed at 
a much higher level compared to the level of the genomic AcrB, indicating that the lack of 




To determine if a mutation in the substrate binding pocket of AcrB (F610A) affects 
interaction between AcrB and AcrA, we used the disulfide bond pairs as described above 
and introduced an additional AcrB F610A mutation (Figure 3.2b). Similar as in Figure 
3.1b, AcrA-AcrB complexes were observed, similar as in samples without the F610A 
mutation, suggesting that the AcrB F610A mutant still binds with AcrA. 
 
Figure 3.2 Characterization of AcrB mutants defective in substrate binding. 
(a) The point mutation did not affect expression level. Anti-AcrB Western blot analysis of 
basal expression of all three mutants and the wild type AcrB from plasmid transformed 
into BW25113. Sample prepared from plasmid-free BW25113 (\) was also prepared and 
loaded to serve as a control to highlight the difference in expression levels. (b) Anti-AcrB 
and Anti-AcrA Western blot analyses revealing the formation of disulfide bonded AcrA-
AcrB complexes, which was reduced after incubation with BME. AcrA-P57C/AcrB-
N191C, F610A is in lane 1 and 3, and AcrA-T217C/AcrB-S258C, F610A in lane 2 and 4. 
Molecular weight markers are labeled as “M” and the molecular weight of bands (kD) were 
indicated on the right. The expected bands for AcrA, AcrB, and disulfide bond linked 
AcrA-AcrB are marked on the left of the gels as A, B, and AB, respectively. 
 
 
3.3.3 Slow Dissociation of the AcrAB Complex 
 
We speculate that the AcrAB complex, once formed, dissociates very slowly. To 




histag at the C-terminus (AcrA-his) into a wild-type and the corresponding acrA knockout 
strains. We first confirmed that under our experimental condition, the genomic AcrB could 
not be purified using metal affinity chromatography (Figure 3.3a). In the absence of the 
plasmid, no AcrB could be detected in the eluate in anti-AcrB Western blot. In contrast, 
when AcrA-his was introduced into the cells, AcrB could be detected in the eluates, 
indicating that it was co-purified through interaction with AcrA-his. Interestingly, the AcrB 
band intensity was higher in the eluate prepared from the acrA knockout strain, indicating 
more AcrB were co-purified. Next, we examined the time course of co-purification. The 
rationale is, in the wild-type strain, genomic AcrB and AcrA form stable complexes. If the 
dissociation is fast, the introduced AcrA-his will quickly compete with genomic AcrA to 
form a complex with AcrB, and in turn enable purification of AcrB through metal affinity 
chromatography. Otherwise, if the dissociation is slow, then it takes much longer for the 
competition to happen. We monitored the formation of AcrAB complex between the 
genomic AcrB and plasmid-expressed AcrA-his at three-time points, right after the 
induction period, and 5 and 17 h after induction (Figure 3.3 b). We performed crosslinking 
right before protein extraction and purification to stabilize the complexes. As a control 
experiment, we also examined the formation of the AcrAB complex between the genomic 
AcrB and plasmid-expressed AcrA-his in an acrA gene knock-out strain. In this case, we 
do not expect competition from the genomic AcrA; thus complex should form faster. We 
found that the formation of the complex is plateaued much faster in the acrA knockout 
strain, as intensities of the eluates prepared from 5 and 17 h into incubation were very 
similar. In contrast, it took much longer for AcrB to interact with AcrA-his in the wild type 
strain, which is likely due to the requirement of an extra step of AcrAB dissociation 





Figure 3.3 Co-purification of genomic AcrB with AcrA-his. 
(a) Anti-AcrB Western blot analyses of samples prepared from BW25113 or 
BW25113ΔacrA with or without plasmid-encoded AcrA-his. (b) Anti-AcrB Western blot 
analyses of samples collected after 0, 5, or 17 h of incubation following the induction of 
AcrA-his production in BW25113 or BW25113ΔacrA strains. Dithiobis-(succinimidyl 
proprionate) (DSP) crosslinking was performed to stabilize the AcrAB complex before 
protein purification. Reduction using dithiothreitol (DTT) breaks the disulfide bond in the 
linker of DSP and the complex into AcrA and AcrB subunits. Molecular weight markers 
are labeled as “M”, and the molecular weight of bands (kD) were indicated on the right. 
The expected bands for AcrB and DSP linked AcrA-AcrB are marked on the left of the 
gels as B and AB, respectively. 
3.4 Discussion 
The dominant negative effect describes the situation in which the phenotype is dominated 
by the negative impact of the functionless mutant. The observation of the dominant 
negative effect has been used in many studies to investigate the mechanism of protein–
protein interaction, including the identification of protein–protein interactions interface 164, 
determination of enzymatic activity related to oligomerization 165, and the effect of 




In the process of AcrAB-TolC assembly, there are many steps where the incorporation of 
a functionless AcrA or AcrB mutant would negatively impact the efflux activity. First, all 
three proteins in the system are oligomers. AcrB and TolC are obligate timers, while AcrA 
is believed to exist as a dimer or trimer in the free form and assembles into a hexamer in 
the pump complex 59, 168. While AcrA and AcrB are believed to form a complex in the 
absence of substrate and efflux, TolC assembles with AcrAB during active efflux. When a 
functionless AcrB mutant is expressed in excess in a wild type E. coli cell containing 
genomic AcrB, we expect them to compete with their genomic counterpart to engage 
genomic AcrA, forming non-functional interactions to reduce the overall efflux activity. In 
addition, we expect the competition for genomic TolC will further enhance the dominant 
negative effect. For this competition to occur, we chose mutants that are defective due to 
mechanisms not directly related to the interaction between AcrA and AcrB. The structure 
of the AcrAB-TolC complex and location of mutants mentioned in this study are shown in 
Figure 3.4.  
We determined the expression level of the mutants relative to their genomic 
counterpart. Using serial dilution and quantitative Western blot analysis, we found that the 
expression levels of the AcrB mutants were 10–20 folds of the level of the genomic AcrB. 
With this high level of excess, we expect to observe a strong dominant-negative effect if 
the mutants were actively involved in the pump assembly, competing for binding partners. 
We constructed two groups of AcrB mutants, defective in different aspects. We observed 
that the effect of certain mutations was not always the same for different substrates. For 
example, T978A mutation in AcrB is detrimental to all substrates tested except for R6G, 
while F178A mutation in AcrB drastically reduced the MIC for ERY, but not as much for 
other substrates tested. This difference in mutation effects has been observed in many 
studies characterizing AcrA and AcrB mutants, for example, 62, 100, 169. We speculate that 
this difference could be due to differences in the binding and interaction of specific 
substrates with the pump complex. The substrates vary drastically in their size, shape, 
structure, and charged state. As a result, the subgroup of residues that they interact with on 
their way to be transported are not likely to completely overlap. Therefore, point mutations 
introduced in AcrA and AcrB could have different impacts on specific substrates. 
63 
Figure 3.4 Structure of the AcrAB-TolC complex with the residues mutated in this study 
highlighted in AcrB structure. 
AcrB mutations are labelled as; B1-F178A, B2-I278A, B3-D407A, B4-D408A, B5-
F610A, B6-K940A, B7-R971A, B8-T978A. AcrAB crystal structure is created using 
pymol from 5N5G.pdb (https://pymol.org/2/)   
Mutants defective in the proton translocation pathway still form trimers 158 and 
interact properly with AcrA (Figure 3.1c). Then, was why no dominant negative effect 
observed? One possibility is that the genomic AcrA and AcrB are transcribed together, 
sharing the same mRNA. Hence, the newly produced AcrA and AcrB could be clustered 
as well. As a result, the genomic AcrA and AcrB form a AcrAB complex as soon as they 
are translated and inserted into the membrane (AcrB) or secreted into the periplasm with 
lipid anchoring (AcrA). Since the local concentration of the genomic proteins are high, 
they associate with each other with a much higher chance than associate with a plasmid-
encoded partner. Another requirement for the observed activity is that the AcrAB complex, 
once formed, should be resistant to dissociation. Otherwise, the high concentration of AcrB 
mutant in the cell membrane would be effective in competing with genomic AcrB to form 




CHAPTER 4. Study of multi-drug efflux system protein degradation 
in E.coli using transposons library 
4.1  Introduction 
The pathogens have evolved different mechanisms for their survival. The antibiotic 
resistance in the pathogens is one such significant evolvement. Moreover, some pathogens 
have acquired the mechanisms to resist multiple drugs. These have created problems in the 
treatment of infectious diseases. There are several major mechanisms from which microbes 
develop drug resistance, including i) genetic mutation or enzymatic alteration ii) 
inactivation of drugs by enzymatic degradation, iii) antibiotic modification, iv) Loss of 
porin and changes in membrane permeability, v) alteration of the drug target, and vi) 
overexpression of efflux pumps17, 170. Our research work is mainly focused on studying a 
multidrug resistance mechanism known as active efflux. Our primary focus is on the 
Resistance-Nodulation-Division (RND) superfamily member AcrAB-TolC efflux pumps 
in E. coli. AcrAB-TolC forms a tripartite complex that spans the inner membrane, 
periplasmic space, and outer membrane of E. coli 137. The pump assembles by inner 
membrane AcrB associating with periplasmic protein AcrA, and outer membrane channel 
TolC44, 46, 171. Inner membrane transporter AcrB plays a pivotal role in substrate 
recognition, binding, and translocation to the exit channel70, 172. Hence, the researchers 
focus on identifying methods to disrupt the AcrB either by targeting substrate binding sites, 
inhibiting pump assembly, or protein degradation methods113, 157. This chapter focuses on 
the identification of novel protease mechanisms important in AcrB degradation. 
Protein degradation in both prokaryotes and eukaryotes require energy input, 
typically by hydrolysis of ATP. In prokaryotes, the proteins are degraded by an ATP-
dependent pathway involving proteases including ClpAP, ClpXP, FtsH, and Lon104, 112, 173. 
Two well-studied examples are AAA+ proteases ClpAP and ClpXP. Protein degradation 
by ClpXP and ClpAP is initiated by recognizing the specific protein for degradation105. 
Signals for degradation include the C terminal tagging of the protein by the ssrA tag or N-




In an effort to study the lifetime of AcrB in E. coli cells, Chai et al., discovered that 
the introduction of a small peptide tag, the small stable RNA A (ssrA)  tag introduced at 
the C terminus of AcrB facilitates complete degradation of AcrB113. The ssrA is a 11 amino 
acid residue tag (Amino Acid sequence-AANDENYALAA). The natural function of ssrA 
is to rescue the stalled ribosomes on truncated mRNA lacking the stop codon110, 175. The 
ssrA tag is added to the C-terminus of the incompletely synthesized proteins during 
translation. ClpP, ClpX, and a chaperon SspB have been identified to be involved in the 
degradation of ssrA tagged AcrB. However, partial degradation was observed when these 
genes were disrupted, indicating that other players were likely involved in the process113. 
The goal of the study described in this chapter is to discover novel proteases and 
protein degradation mechanisms that are involved in the destruction of AcrB. Specifically 
for this purpose, the transposons library has been created, which contains an extensive 
collection of strains with random gene knockouts. Transposable elements are generally 
known as "jumping genes/selfish genes." These DNA sequences move from one location 
to another in the genome118, 126. The identification of transposons has led to significant 
discoveries in various scientific aspects116, 118. The main problem associated with genome 
studies in sequencing large DNA segments is sequencing an insert within the interior of a 
DNA. Alternative techniques have been developed, such as genome walking/ primer 
walking and shotgun subcloning, to overcome these restrictions118. The Tn5 transposons 
system, which has the cut and pastes mechanism, has been widely used in different 
studies120, 129. Transposons library creations have facilitated the identification of genes 
involved in virulence and other non-essential processes125. Furthermore, to get insight into 
the essential gene, gene function, and genetic linkages, sophisticated deep DNA 
sequencing approaches have been influential in the use of transposon libraries. The Tn5 
transposons system have been used in our study, which comes under the group of 
composite transposons121 
Comparatively, an E.coli strain containing AcrB-WT has a higher tolerance to 
antibiotics than a strain containing AcrB-ssrA. Hence, in this study, the first goal was to 
establish a screening strategy to identify antibiotic concentrations under which strain 
containing AcrB-WT would grow but not those containing AcrB-ssrA. Next, plasmid 




transposome system. The transposon has a kanamycin resistance marker, allowing mutants 
to be selected when the transposon is inserted into the recipient strain's genome. Insertion 
of the transposon is random, and thus we speculate there is an opportunity for it to disrupt 
genes important for the degradation of AcrB-ssrA. In this case, the expression level of 
AcrB-ssrA would be higher in the strain, and thus lead to higher tolerance of antibiotics 
that are substrates of AcrB. The elevated level of AcrB-ssrA expression was then 
confirmed using anti-AcrB antibody and Minimum inhibitory concentration assays. PCR-
based sequencing methods and finally, the next-generation sequencing method (NGS) was 
used to determine the transposons inserted gene location. Data analyses revealed the clpX 
gene was disrupted in the strains with elevated levels of AcrB-ssrA expression. 
 
 
4.2 Material and Methods  
 
4.2.1  Knockout strain creation, competent cell preparation and Transformation 
BW25113 wild-type strain was obtained from Yale E. coli genetic resources. 
BW25113∆acrB was produced in the lab using the E. coli gene deletion kit (Cat #K006, 
Gene Bridge). The same kit was used to remove the kanamycin cassette to obtain the cells 
without kanamycin resistance (BW25113∆acrB; K-). Next, to incorporate the ssrA into the 
system, competent cell preparation was done, followed by the transformation. E. coli 
BW25113∆acrB; K- were transformed with the pQE70 AcrB -ssrA (ampicillin resistance-
Amp+) plasmid and plated on Luria broth (LB)-Amp+ plate following the incubation at 
37°C overnight. Furthermore, pQE70 AcrB WT was transformed into E. coli 
BW25113∆acrB; K- and BW25113 WT cells; pQE70 AcrB WT and pQE70 AcrB ssrA 
into BW25113∆clpX cells. These were later used in minimum inhibitory concentration 
(MIC) assay. 
Preparation of BW25113∆acrB; K- pQE70 AcrB- ssrA competent cells: A single 
colony was picked from the LB-Amp+ plate and used to inoculate 5 mL of fresh LB 
containing ampicillin (100 mg/mL; 1:1000 dilution). The culture was incubated at 37°C 




using 500 µL of the overnight culture. The new culture was incubated at 37°C until its 
OD600 reached 0.5, which was used for the electrocompetent cell preparation. The culture 
was kept on ice for ~ 20 mins and then centrifuged at 2400rpm for 20 mins at 4°C followed 
by resuspension with ice-cold sterile distilled water (100 mL). Next, it was centrifuged at 
2400rpm for 20 mins at 4°C. The washing step with ddH2O was repeated. Then the cell 
pellets were resuspended in 10% ice-cold glycerol (40 mL) and centrifuged at the same 
conditions. The glycerol wash step was repeated one more time, and the supernatant was 
removed. The pellet was resuspended in 0.2mL of 10% glycerol. 
The prepared BW25113∆acrB; K- pQE70 AcrB -ssrA electrocompetent cells 
(Amp+) were used for the transposomes insertion and MIC assays described in the below 
sections. 
 
4.2.2 The Minimum Inhibitory Concentration (MIC) LB agar plate assay and liquid 
assays to compare the growth of different E. coli strains. 
 
The first step in creating the transposons library is to identify a reliable screening 
method to use after the insertion of transposomes. For our purpose, we need to identify a 
condition in which the BW25113∆acrB containing pQE70 AcrB ssrA cells do not grow, 
while the BW25113∆acrB containing pQE70 AcrB WT cells grow. The BW25113∆acrB 
pQE70 AcrB WT strain, containing a higher level of AcrB, should be more tolerant to 
AcrB substrate than BW25113∆acrB pQE70 AcrB ssrA, in which the expression of AcrB-
ssrA was significantly reduced. The condition in which only the BW25113∆acrB pQE70 
AcrB WT strain, but not the BW25113∆acrB pQE70 AcrB- ssrA strain grows, will be used 
to screen for new mutants that have gene disruptions that lead to functional loss of other 
proteins that are involved in AcrB-ssrA degradation. We expect to rediscover ClpX, ClpP, 
and SspB in our screening, which will serve as a positive control for the effectiveness of 
our screening method. In addition, we are looking for novel genes where the disruption 
will also lead to the survival of the strain. The following MIC assays were performed to 
find conditions of efficient screening assay. Two known AcrB substrates were tested, 




The LB agar plates with different antibiotic concentrations ranging from 100-20 
µg/mL for novobiocin and erythromycin were prepared.  To each plate 15 µg/mL of 
kanamycin was added as the second substrate. 5mL cultures at OD 0.5 was used for the 
experiment. We expect the concentration in the culture is 5x108 per mL. A dilution series 
was prepared from 109 to 104. After establishing a screening method, the next step was to 
create a random insertion library using a transposome system.  
Liquid MIC assay was performed for the BW25113 ∆acrB pQE70 AcrB WT, 
BW25113 ∆acrB pQE70 AcrB ssrA, BW25113 pQE70 AcrB WT, BW25113 pQE70 AcrB 
ssrA, BW25113 ∆clpX pQE70 AcrB WT and BW25113 ∆clpX pQE70 AcrB ssrA strains 
using NOV and ERY. 
 
4.2.3 Electroporation of BW25113 ∆acrB pQE70 AcrB ssrA electrocompetent cells 
with EZ-Tn5 <KAN-2>Tnp transposome and selection of transposed clones  
 
The insertion of transposons to create the random mutations was achieved using the 
Lucigen Ez-Tn5TM <Kan-2> Tnp TransposomeTM kit (Cat # TSM99K2). The transposons 
insertion was done by electroporation of the BW25113 ∆acrB pQE70 AcrB ssrA 
electrocompetent cells (Amp+) with one microliter EZ-Tn5 <KAN-2>Tnp Transposome. 
Electroporated at 2200 V, using a 2 mm cuvette, for ~5.7 ms using Eppendorf Eporator®, 
(Catalog #4309000019). The electroporated cells was immediately recovered after 
electroporation using Super Optimal broth with Catabolite repression (SOC) medium; 
(0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM Glucose). SOC medium was added to the electroporation cuvette to 1 mL 
final volume immediately after electroporation. The medium was pipetted gently to mix 






Figure 4.1 The schematic representation of the transposons library creation using 
electroporation method. 
The image is belongs to Lucigen Inc. (https://www.lucigen.com/docs/slide-decks/Lucigen-
EZ-Tn5-Transposon-Tools.pdf) 
 
The control experiment was conducted using pET28a sfGFP plasmid (Kan+) 
electroporated in to the BW25113 ∆acrB pQE70 AcrB ssrA electrocompetent cells 
(Amp+). Then 100 μL aliquots of the recovered cells were plated on plates containing 50 
μg/mL and 15 μg/mL kanamycin- for control and experimental samples, respectively. The 
transposome inserted sample was plated on kanamycin (15 μg/mL) included different 
antibiotic plates; NOV- 20 μg/mL, 40 μg/mL and ERY 20, 40 μg/mL. All the plates were 
incubated at 37°C incubators overnight (~16hrs). The rest of the recovered cultures were 
stored at 4°C. The next day, the plates were checked for colonies. Next, colonies were 
chosen from each plate and used to inoculate 3 mL cultures overnight; simultaneously, 
each colony chosen was streaked on a new plate, and a number was assigned for each 








4.2.4 Inhibition by Phenylalanine-Arginine-β-naphthylamide dihydrochloride 
(PAβN) Efflux pump inhibitor to confirm the elevation of MIC is due to 
AcrB activity 
 
To confirm the observed effect on MIC depends on the AcrB expression, the efflux 
pump inhibitor PAβN (MCE; Cat# HY-101444A) was used to inhibit AcrB-mediated 
efflux using samples that have been selected from the previous MIC assays with ERY. 
The antibiotic concentration for erythromycin was decided based on the previous 
MIC results. The assay with inhibitor was optimized by using a concentration range of 
PAβN (10, 20, 30, 40, and 50 µg/mL) with 1 mM Mg2+. Magnesium was used to avoid the 
outer membrane disruption that can be caused by the high concentration of inhibitor. From 
the screening, 50 µg/mL of inhibitor was selected and used for the MIC assay. After 
overnight (~16 hrs) incubation, the plate reading was taken using the plate reader at OD 
600 nm. The sample number finalized through this inhibitor assay, and the second phase 
of the MIC assay proceeded for the western blot analysis, genomic DNA extraction, and 
sequencing. 
 
4.2.5 FLAG tag insertion, Western Blot analysis with Anti AcrB CT and FLAG 
antibody 
 
The selected samples were used to prepare 5 mL overnight LB cultures. The next 
day these cultures were centrifuged to obtain the cell pellet.  The cell pellet was 
resuspended in 50 µl of the lysis buffer (PBS (pH 7.5), 2.5 mM MgCl2, 0.5mM CaCl2, 10 
µM DNase (Final pH 7.6) and 50 µl SDS loading dye (Tris-HCl, pH 6.8, 6%SDS, 48% 
glycerol, 0.03% bromophenol blue, 9% 2-Mercaptoethanol). The samples were incubated 
at 37oC for 30 mins, centrifuged at max speed (150,000 rpm) for 1 minute, and the 
supernatant was subjected to the SDS PAGE analysis. The SDS-PAGE electrophoresis was 
done at 220 V for 40 mins using 15% SDS gel. Then the gel was transferred to a 
Polyvinylidene difluoride (PVDF) membrane stack between the blotting papers. The 
transfer was done at 380 V for 25 mins, and then blot was proceeded for the western blot 
analysis. Briefly, the PVDF membrane was incubated in the blocking solution (5% skim 
milk powder+ Tris Buffered Saline (TBS) buffer; Tris-HCl, NaCl pH 8.0) for 1 hr. at room 




antibody (1:5000 antibody in TBS buffer). The membrane was incubated for 1.5 hrs at 
room temperature.  The membrane wash was performed using wash buffer (TBS + 1:1000 
tween 20) 3 times,  10 mins each time. Then the membrane was transferred to a TBS buffer 
containing the Anti Goat to Rabbit secondary antibody (1:5000 in TBS buffer). The blot 
was Incubated for 45 mins with the antibody, followed by washing as described above. 
Then the BCIP/NBT (5-bromo-4-chloro-3'-indolyphosphate and nitro-blue tetrazolium) 
solution was used for staining the membranes and shake until the color is developed.  
Another plasmid construct was created in which the FLAG tag was inserted at the 
N terminus of the pQE70 AcrB-WT and pQE70 AcrB-ssrA plasmids using the fast cloning 
method156. The BW25113 ∆acrB pQE70 FLAG AcrB WT and BW25113 ∆acrB pQE70 
FLAG AcrB ssrA used for the Western blot analysis with anti- FLAG antibody. The same 
procedure was followed with Anti FLAG antibody (Santa Cruz Biotechnology). 
 
4.2.6 Genomic DNA extraction and sequencing  
 
Genomic DNA was extracted from colonies that show promising results from the 
MIC assay and processed for sequencing to identify the candidate genes. As the first step, 
1.5 mL of overnight cultures were prepared from colonies identified through MIC assays. 
The PureLink™ Genomic DNA Mini Kit (Cat#:K182001, Thermofisher) was used in 
genomic DNA extraction. Briefly, the method is as follows: 
The cells were harvested at 9000 rpm for 5 mins. Then those were proceeded to 
prepare the lysate using Pure link genomic Kit. First, 180 µl of the digestion buffer +20 µl 
of Proteinase K was added, vortexed briefly, and incubated at 55oC for 1 hr. with occasional 
vortexing (5s vortex). Then 20 µl of RNase was added, vortexed, and incubated at room 
temperature for 2 mins. After that, 200 µl of lysis buffer+200 µl of 99.5% Ethanol was 
added, followed by vortexing and mixing of samples. Next, the lysate was transferred to 
the spin column and centrifuged at 9,000 rpm for 1 min at room temperature. The next step 
was washing. First 1,500 µl wash buffer was added and centrifuged at 9000 rpm for1min, 
next 500 µl wash buffer was added and centrifuged at 15,000 rpm for 3 mins. Genomic 
DNA was eluted by adding 30 µl of elution buffer, incubating for 1 min at room 




another collection tube with 30 µl of elution buffer. Agarose gel electrophoresis was 
performed to check the presence of DNA. Furthermore, a survey scan was done at 
wavelengths 260 nm and 280 nm to check the DNA quality. 
 
4.2.7 Sequencing results analysis and identified gene verification 
 
The samples were pooled and sent for Nest Generation Sequencing (NGS) (in 
collaboration with China). The extracted genomic DNA was sequenced using long-read 
MinION (Oxford Nanopore) and short-read Illumina MiSeq technologies. The long reads 
were generated by Oxford Nanopore MinION flowcell R9.4 with a depth more than 300 
times and the 150 bp paired-end short reads were generated by Illumina MiSeq system 
(Illumina, San Diego, CA, United States) with a depth more than 100 times. The MinION 
reads were filtered using Filtlong (version 0.2.0) to remove any reads < 2000 bp, followed 
by removing the lowest 10% of reads by quality. Complete sequence assembly was 
performed with Canu version 1.5 using a combination of short and long reads, followed by 
error correction by Pilon version 1.12. 
The sequences for each sample were used in the NCBI; nucleotide to nucleotide 
Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequence was entered in the FASTA 
format, and the reference sequence accession number for Escherichia coli str. K-12 substr. 
MG1655, complete genome Escherichia coli str. K-12 substr. MG16554,641,652 bp 
genomic sequence was given as U00096.3. As shown in the following image either the 
highly similar or somewhat similar sequence options were selected and performed the blast 
(Figure 4.2). 
The gene sequence was checked using the ClustalX2 software to match up the 
regions aligning in the sample sequence and candidate gene sequence for further 
confirmation. This process was followed for all the samples to find out the disrupted genes. 
First, the verification of the kanamycin gene in the identified gene location was performed 
using primers to amplify the Kanamycin cassette. Next, further analyses were done to 
determine any other possible genes disrupted by Tn5 transposons insertion. The primers 






Figure 4.2 The figure illustrates the query and subject sequences entering and the 




Table 4.1 Primers used for the verification process 
 
Primer  Primer sequence 5’-3’ 
KAN-verification-F:  AACACGTAGAAAGCCAGTCCG 
KAN-verification-R:  CCCCTGATGCTCTTCGTCCA 
Tn5-clpX-verification-F： CGATTCGATTCTGACCCATC 
Tn5-clpX-verification-R： CGTCAGTATATGGGGATGTTTC 
Clpp verification-F ATGTCATACAGCGGCGAAC 
Clpp verification-R CAATTACGATGGGTCAGAATCG 
SspB verification-F： ATGGATTTGTCACAGCTAACAC 







4.3 Results and Discussion 
 
4.3.1 Minimum inhibitory concentrations for pQE70 AcrB-ssrA and pQE70 AcrB 
WT strains in BW25113 ∆acrB 
 
The identification of a proper condition is essential for the establishment of an 
efficient screening assay. As for the first step, we performed the MIC assay. This technique 
is used to determine the lowest concentration of an antibiotic that inhibits the growth of a 
bacteria. MIC assay is an easy method that can be done on a small scale. This assay can be 
performed either in a liquid medium or solid medium. However, the most prominent 
process is the liquid assay. During MIC measurement, serial dilutions of different 
antibiotics are added to the growth medium. In this experiment, we used two different 
antibiotics for liquid assay and solid assay. Table 4.2 summarizes the MIC values for each 
of the strains for different antibiotics for liquid assay. Figure 4.2 shows the differential 
growth of the wild type (WT) and ssrA strain to varying concentrations of novobiocin and 
erythromycin. During the actual screening, cells are be plated onto agar plates (solid assay). 
The liquid assay is used here to identify the proper concentration range. The rationale is 
that differences in protein expression level (AcrB-ssrA is less than WT AcrB) will lead to 
a smaller MIC for the strain containing AcrB-ssrA. Once we have identified a suitable 
substrate and a concentration, we will be able to select mutants containing gene deletions, 
enhancing the expression level of AcrB-ssrA. Thus, this gene/s is likely to be involved in 
the degradation of AcrB-ssrA.  
Erythromycin is a macrolide antibiotic that participates in the inhibition of protein 
synthesis by binding to the 50S subunit of the ribosome during translation in bacteria. 
Novobiocin is an aminocoumarin that binds to DNA gyrase and acts as a competitive 
inhibitor of ATPase activity. A two-fold or four-fold difference in MIC values has been 
observed for strains containing either the WT or the ssrA tagged constructs. Thus, these 
two substrates could be used in the screening. The LB agar assay results facilitate 
identifying the proper concentration for the establishment of transposons library screening. 
As shown in Figure 4.2, at very low concentrations a (10 µg/mL) and very high 
concentrations d (100 µg/mL), the difference between WT and ssrA is insignificant. 




be observed between the two samples. Therefore, those are suitable conditions for 
screening.  
 
Table 4.2 The MIC values for pQE70 AcrB-ssrA and pQE70 AcrB WT strains in BW25113 
∆acrB, WT and ∆clpX 
 
 NOV ERY 
BW25113 ∆acrB containing   
pQE70 AcrB WT 320 160 
pQE70 AcrB ssrA 80 40 
BW25113 containing   
pQE70 AcrB WT 640 320 
pQE70 AcrB ssrA 160 80 
BW25113 ∆clpX   
pQE70 AcrB WT 640 320 











Figure 4.3 A representation of the streaking pattern on the LB agar plate used for the solid 
assay. 
The dilution series ranges from 109 to 104. The top half of the plate was spotted using the 
WT strain, and the bottom half of the plate was spotted with ssrA strain. (the bottom should 
be labeled similarly as the top) B) This image shows the results obtained in a solid assay 
using NOV and ERY. All the plates contain 15 µg/mL concentration of kanamycin. 
Concentrations of NOV or ERY in each panel as; a) 10 µg/mL b) 20 µg/mL c) 40 µg/mL 













4.3.2 The Ez-Tn5 transposons insertion by electroporation 
 
The random insertion of the transposons was performed using the electroporation 
method. Figure 4.4 displays the colony growth of the control and the experimental strains 
with different concentrations of the antibiotics. In these experiments, different antibiotic 
concentrations were fine-tuned. The kanamycin 50 µg/mL control plate has many colonies; 
the pET28a sf-GFP control is intrinsically kanamycin-resistant (Figure 4.4 A). This result 
demonstrated that the electroporation transformation was successful. BW25113 ∆acrB 
pQE70-AcrB-ssrA with transposome insertion on kanamycin 15 µg/mL plate also has a 
higher number of colonies (Figure 4.4 B). The BW25113 ∆acrB pQE70-AcrB-ssrA cells 
do not have intrinsic resistance to kanamycin. Hence, this reveals transposons insertion is 
successful. 
Plates containing LB-agar with different NOV, ERY concentrations, and 
kanamycin (15 µg/mL) allow for the selection of colonies with an expression similar to 
AcrB-WT. Because, under these low NOV or ERY concentrations, the BW25113 ∆acrB 
pQE70-AcrB-ssrA strain does not show significant growth. The growth at these 
concentrations will show that there might be a mutation of the genome of the strain 
containing AcrB-ssrA that increased its expression level (and thus drug tolerance) (Figure 
4.4 C, D, E). 
The colonies picked from these plates were subjected to further liquid MIC assays 
to confirm that they grow at higher antibiotic concentrations. The same two substrates were 
used for the liquid assay (Table 4.3).  The samples show similar or higher MIC values than 
the WT strain, implying that the AcrB expression has increased despite ssrA. Hence, there 






Figure 4.4 The colony growth of the experimental and control strains with transposome 
insertion plated in 
(A) control pET28a sf-GFP in kanamycin 50 µg/mL (B) BW25113 ∆acrB pQE70-AcrB-
ssrA with transposome insertion plated in kanamycin 15 µg/mL. (C), (D), (E) BW25113 
∆acrB pQE70-AcrB-ssrA with transposome insertion plated in Erythromycin 20 µg/mL+ 
kanamycin 15 µg/mL, Novobiocin 40 µg/mL+ kanamycin 15 µg/mL, Erythromycin 40 
µg/mL+ kanamycin 15 µg/mL respectively. Red circle highlights the location of colonies. 
 
 
Table 4.3 The MIC values for samples picked from the transposons library 
 
Sample ERY NOV 
S 1 320 80 
S 2 160 320 
S 3 320 320 
S 4 320 320 
S 5 320 320 








Table 4.3 (Continued) 
S 7 >320 160 
BW25113 ∆acrB; K- 40 40 
BW25113 ∆acrB; K- pQE70 AcrB  WT 160 320 
 
4.3.3 MIC assay with Phenylalanine-Arginine-β-Naphthylamide dihydrochloride 
(PAβN) Efflux pump inhibitor  
 
Several inhibitors have been identified for RND family efflux pumps. These 
inhibitors increase antibiotics efficacy, reduce the pathogen's resistance occurrence, and 
reduce the pathogen's infection ability.Among available Efflux Pump Inhibitors (EPI), 
PAβN is a frequently studied efflux pump inhibitor. EPIs are essential in clinical use to 
inhibit the multidrug resistance of bacteria. We used this inhibitor in our experiment to 
confirm the increase of the MIC value for transposons inserted BW25113 ∆acrB pQE70-
AcrB-ssrA strain was due to the activity of the AcrAB-TolC efflux pump.  
The PAβN is capable of significantly reducing the antibiotic resistance of E. coli 
for selected compounds that are AcrB substrates. The combination of the antibiotics (pump 
substrate) and the inhibitor facilitate the study of efflux-mediated multidrug resistance. 
Under our experimental condition, we observed the inhibitor alone does not influence 
bacterial growth. All the tested colonies grow normally in the presence of the inhibitor. 
However, when it was added along with ERY the colonies had a four-fold decrease in MIC 
values. These observations explain that the previously observed higher MIC values are due 
to the efflux activity of AcrB-ssrA, likely a result of increased expression level due to a 
mutation in a gene that regulates the ssrA tagged protein degradation. 
Table 4.4 shows the results obtained for some of the tested strains. The highlighted 
values show the growth in the examined antibiotic concentration and the strains that were 








Table 4.4 The MIC values for the selected samples in the presence of an antibiotic and with 
or without inhibitors 
 
Sample Inhibitor PAβN (50 µg/mL) 
 
(-) (+) 
S 1 320 80 
S 2 160 80 
S 3 >320 80 
S 4 >320 80 
S 5 >320 80 
S 6 320 160 
S 7 >320 80 
BW25113 ∆acrB; K- 40 40 
BW25113 ∆acrB; K- pQE70 AcrB WT 160 40 
 
 
4.3.4 The selected colony analysis with western blot and sequencing 
 
The above-discussed methods were used for the selection of the colonies that shows 
higher AcrB activity. We tested two vectors for AcrB-ssrA expression, pQE70 AcrB ssrA 
and pQE70- AcrB WT. Furthermore, we created pQE70 FLAG -AcrB- ssrA and pQE70 
FLAG -AcrB WT and used those for initial testing for AcrB expression in BW25113 ∆acrB 
and BW25113 ∆clpX cells (Figure 4.5). The expression of AcrB-ssrA is significantly lower 
in the wt strain compared to the BW25113 ∆clpX strain. This confirms the role of ClpX in 





Figure 4.5 Western blot analysis with anti AcrB-CT and anti-FLAG antibodies. 
(A)1. BW25113 ∆acrB- pQE70 AcrB WT, 2. BW25113 ∆acrB- pQE70 AcrB- ssrA, 3. 
BW25113 ∆clpX- pQE70 AcrB WT and 4. BW25113 ∆clpX- pQE70 AcrB -ssrA.  (B) 
Western blot analysis with Anti FLAG antibody. 1. BW25113 ∆clpX- pQE70 AcrB- ssrA, 
2. BW25113 ∆clpX- pQE70 AcrB WT, 3. BW25113 ∆acrB- pQE70 AcrB- ssrA, and 4. 
BW25113 ∆acrB- pQE70 AcrB WT. 
 
To determine if the AcrB expression in the selected colonies were higher, we 
conducted Western blot analysis using Anti-AcrB antibody. The sample numbers are 
consistent with the numbers on the MIC plates used during selection. For several samples 



















Figure 4.6 Western blot analysis with anti AcrB-CT antibody. 
1) BW25113 ∆acrB; K-.2) BW25113 WT. 3) BW25113 ∆acrB pQE70 AcrB- ssrA. 4) 
BW25113 ∆acrB pQE70 AcrB WT. Lanes 5-11 are samples 1-7 (S1-S7) respectively. 
 
4.3.5 Genomic DNA extraction and sequence analysis. 
 
The genomic DNA was extracted from the selected colonies using the method 
described in material and methods. Then 1% agarose gel was used for the confirmation of 
the presence of genomic DNA. E. coli genomic DNA is ~4.4- 5.5mb. The samples were 
sent for NGS, and the received sequences were analyzed using NCBI and ClustalW 
methods as described in methods.  
To confirm that transpositions was successful and the selected colonies contained 
the kanamycin cassette, we performed PCR to amplify the kanamycin resistance cassette 
(Figure 4.7 A). The agarose gel analysis shows all seven samples have the Tn5 kanamycin 
cassette. The presence of the Tn5 sequence in the clpX gene area confirms transposon 
insertion. Hence, it confirmed clpX as the disrupted gene by the insertion of transposons. 
A PCR was conducted to verify this insertion further. Figure 4.7 B shows the PCR products 
amplify in the clpX region. Once the Tn5 is inserted, the DNA fragment should be longer 
(1591 bp) than a non- disrupted clpX (1539 bp). According to the gel image, samples 
3,4,5,6 migrate slowly compared to samples 1,2,7 and control (BW25113 WT). These 
products were sent for sequencing, and it confirmed the presence of Tn5-clpX. The samples 
1,2,7 sequencing results showed an intact clpX. 
Further analysis was performed to determine which genes disruption is responsible 
for the higher expression and MIC values of samples 1,2 and 7. For that purpose, we 





important roles in AcrB-ssrA degradation. However, the agarose gel image analysis 
exhibited intact clpP and sspB regions (Figure 4.7 C).  
 
 Figure 4.7 Agarose gel electrophoresis analysis of the PCR products. 
A) Confirmation of the presence of Tn5-Kanamycin cassette. B) Confirmation of clpX-Tn5 
insertion. Sample 3,4,5,6 has slow migration. C) Analysis of samples 1.2 and 7. a) analysis 
of sspB region b) Presence of IS4 kanamycin cassette c) Analysis of clpP region 
 
Further analysis is required to identify the disrupted genes that increase the 
expression in samples 1,2 and 7. However, due to the time and resource limitation, this 
project was ended at this point. 
4.4  Conclusion 
Transposons library creation is one of the most versatile tools in genetic studies. It provides 
efficient and robust genetic mutation analysis to identify novel genes for a particular 
function, virulence genes, and non-essential genes. The availability of high throughput 
sequencing methods such as NGS has made the use of transposons much more reliable and 
efficient. Our purpose was to identify novel gene/genes that have an essential role in the 
ssrA tagged AcrB degradation. In the long term, identifying genes important for the AcrB 





reduce the drug efflux through the AcrAB-Tolc efflux pump. Even though the transposons 
library formation in this experiment did not identify novel genes, it identified an already 
known gene clpX. The observed increase in AcrB expression after disruption by transposon 
validates the effectiveness of the strategy. Unfortunately, the size of the library created in 
the current study limited the success of the search. Efficient and more reliable identification 
of novel genes would require the creation of a more extensive transposons library. The 
construction of a large library of mutants is crucial in transposons studies. Multiple 
insertions can be detected in every possible locus in a large, complicated library. The higher 
the insertion density, the more precise the identification of region-of-interest boundaries. 





















CHAPTER 5. Discussion and future work 
 
The RND family efflux pump AcrAB-TolC in E. coli and its homologs in other 
Gram-negative bacteria play significant roles in conferring multidrug resistance to the 
cells. The pump component structures have been investigated through crystallography and 
cryo-EM methods. Even though this structural knowledge has led to the elucidation of the 
substrate efflux mechanisms and pump assembly models, there are still several unanswered 
questions about the AcrAB-Tolc pump system. In this study, our focus was to address three 
major aspects regarding the inner membrane protein of the efflux complex, which is 
responsible for the recognition and binding of compounds before their transportation out 
of the cell.  We have studied the conformational changes in functional rotation, the pump 
assembly process,  and AcrB-ssrA degradation. 
In chapter two, we focused on understanding the dynamics of AcrB during 
functional rotation in the process of drug efflux131. For this purpose, we introduced six 
inter-subunit disulfide bonds into the periplasmic domain of AcrB using site-directed 
mutagenesis. The goal was to study the importance of the relative flexibility at the inter-
subunit interface. We utilized MIC, Western blot analysis, and EtBr efflux assay. The 
formation of disulfide bond-linked AcrB oligomers, which were reduced into monomers 
under reducing conditions, was analyzed through Western blot. We evaluated the impact 
of mutation and formation of disulfide bond on efflux through comparison of the minimum 
inhibitory concentration (MIC) of an AcrB knockout strain expressing different mutants. 
Furthermore, ethidium bromide accumulation assay was used to determine if the 
reduction of activity in a double mutant is due to restriction on conformational changes by 
the disulfide bond formation. We used dithiothreitol (DTT) as the reducing agent. In two 
cases, the activities of the double Cys mutants were partially restored by DTT reduction, 
confirming the importance of relative movement in the respective location for function. 
Nile red assay is another efflux quantification method that could have used for this study176. 
To extend this study, identifying more potential disulfide bond forming locations 
and studying their impact would be necessary. Ultimately, these findings provide new 




Chapter three discussed the effect of over-expressing functionally defective pump 
components in wild-type E. coli cells to probe the pump assembly process153. In this study, 
we utilized the "dominant-negative" effect concept.  Based on previous studies, the 
incorporation of a defective component to the pump is expected to reduce the efflux 
efficiency of the complex.  When considering pump components separately,  mutations in 
AcrB have been reported to disrupt efflux through different mechanisms. We examined 
proton translocation pathway and substrate binding pathway mutants and found that none 
demonstrated the expected dominant-negative effect. Our current data reveals that the 
AcrAB-TolC complex assembly appears to have a proof-read mechanism that effectively 
eliminated the formation of a futile pump complex. We used MIC and expression analysis 
through Western blot as basic study methods. However, to investigate the efflux efficiency 
of the defective pump components, incorporating Nile red assay would be beneficial. 
Moreover, further studies of the pump assembly can perform regarding other elements in 
the efflux pump. Thorough investigation would provide a better picture about the pump 
assembly process.  
The next question we wanted to answer was regarding the ArB degradation. A 
previous study from our group revealed that AcrB tagged by ssrA at the C-terminus 
facilitated degradation of the protein by ClpXP proteases113. In this project, we focused on 
exploring other protein degradation mechanisms or proteases involve in AcrB-ssrA 
degradation. For this purpose, we used transposons as the primary tool. We hypothesize 
that the increased activity of AcrB-ssrA protein is due to a mutation or inactivation of a 
gene involved in the degradation of AcrB-ssrA. Through gene sequence analysis, we 
identified clpX as the gene location disrupted by transposons insertion. Since clpX is an 
already recognized and widely studied protease system, this is not a novel finding. 
However, this finding validates our transposons library creation and screening methods.  
It is essential to have an extensive transposons library. It would provide more 
flexibility and a wide range of gene disruptions to explore. In future work, creating a 
transposons library with many mutants should be the first step in this project. One of the 
significant challenges in this project was the identification of transposons inserted location. 
Initially, we used several sequence analysis methods, such as Random Amplification of 




previous literature177-179. However, these methods did not provide good sequencing results, 
which led us to use the next-generation sequencing (NGS) method. NGS is an expensive 
method; hence, in continuing this project, one of the primary focuses should be a more 
reliable, inexpensive, and effective transposons location identification method.  
The following steps after identifying a specific gene include a complete analysis of 
the effects of the gene. The primary focus will be on verifying the potential role of the 
identified protein in membrane protein degradation, using molecular cloning, protein 
expression, and purification methods. Utilizing this information to determine its structure 
and potential function using available literature and genomic sequence can be the next step. 
The potential function information will be helpful in experimentally testing possible 
hypotheses. Moreover, investigating its role in the ssrA-facilitated degradation of other 
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